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Abstract 
 
ESAC, the EURL ECVAM Scientific Advisory Committee, advises EURL ECVAM on scientific 
issues. Its main role is to conduct independent peer review of validation studies of 
alternative test methods and to assess their scientific validity for a given purpose. The 
committee reviews the appropriateness of study design and management, the quality of 
results obtained and the plausibility of the conclusions drawn. ESAC peer reviews are 
formally initiated with a EURL ECVAM Request for ESAC Advice, which provides the 
necessary background for the peer-review and establishes its objectives, timelines and 
the questions to be addressed. The peer review is normally prepared by specialised ESAC 
Working Groups. These are typically composed of ESAC members and other external 
experts relevant to the test method under review. These experts may be nominated by 
ESAC, EURL ECVAM and partner organisations within the International Cooperation on 
Alternative Test Methods (ICATM). ESAC ultimately decides on the composition of these 
Working Groups. ESAC's advice to EURL ECVAM is formally provided as 'ESAC Opinions' 
and 'Working Group Reports' at the end of the peer review. ESAC may also issue 
Opinions on other scientific issues of relevance to the work and mission of EURL ECVAM 
but not directly related to a specific alternative test method.   
The ESAC Opinion expressed in this report relates to the peer-review of the Ocular 
Irritection® test method for prediction of serious eye damage/eye irritation potential of 
chemicals. 
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Ispra, 24 June 2016 
ESAC Opinion 
In April 2016, the EURL ECVAM Scientific Advisory Committee (ESAC) (Annex 1) received 
from EURL ECVAM a request for scientific advice on the external prospective and 
retrospective validation of the Ocular Irritection® (OI) test method for serious eye 
damage/eye irritation testing (Annex 2). ESAC established a working group (WG) (Annex 
1) which delivered an ESAC WG report dated 6 June 2016 (Annex 3).
The ESAC WG was established to conduct a peer review of, and provide scientific advice 
on a multi-laboratory trial involving three laboratories supplemented by additional 
retrospective data and analysis of the OI assay, a test method claimed to have a wide 
applicability domain. In particular the ESAC WG was asked to consider the relevance 
(biological/mechanistic relevance and predictive capacity; the latter in the context of an 
Integrated Approach to Testing and Assessment (IATA) (OECD, 2008)), and the reliability 
(transferability; within and between laboratory reproducibility) of the test method.  
In addition the ESAC WG was asked to comment on draft Performance Standards (PS). 
The analysis and conclusions of the ESAC WG were based primarily on the EURL ECVAM 
Test Submission Template (TST) and supporting documents supplied by SeCAM on behalf 
of the test manufacturer, and supplementary information made available by SeCAM 
during and after an 11 May 2016 teleconference.  
Details of the validation study were previously published by Eskes et al. (2014). 
The prospective and retrospective OI assay validation study pre-defined objectives were: 
 To formally evaluate the usefulness of the OI assay to reliably discriminate
chemicals not requiring classification for serious eye damage/eye irritancy (No
Category) from chemicals requiring classification and labelling (Category 1 and
Category 2) according to the UN GHS Classification and Labelling of Chemicals
(UN GHS. UN, 2015) and as implemented by the EU CLP regulation (EU CLP. EC,
2008a). This test method is not intended to differentiate between GHS Categories
1 (irreversible effects) and 2A-B (reversible effects).
o N.B. The test method was not designed, intended, or evaluated to test
gases or aerosols.
 A further post-hoc evaluation was performed to evaluate the usefulness of the OI
assay to discriminate chemicals inducing serious eye damage (UN GHS Category
1) from other classes.
 In addition, to produce evidence and analysis to support the test method being
incorporated into a tiered testing strategy (so-called Bottom-Up/Top-Down testing
strategy, Scott L. et al., 2010). The ultimate purpose of such a tiered testing
strategy being to replace the traditional in vivo Draize eye test [Method B.5 of EC
Regulation 440/2008 (EC, 2008b) or OECD TG 405 (OECD, 2002)].
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At its 42nd meeting, held on the 9th and 10th June 2016 at EURL ECVAM, Ispra, Italy, the 
non-Commission members of ESAC unanimously endorsed the following statement which 
was based on the ESAC WG report: 
The OI assay evolved from the Eytex® test method (Kelly, 1989; Gordon, 1992) following 
recommendations made by Balls et al. (1995). In 1996, the system underwent 
substantial revisions to take into account the recommendations made after the earlier 
multi-laboratory trials including the development of a single protocol, clear procedures 
for surfactant testing, and a well-defined applicability domain. 
The test method is premised on the assumption that eye irritants produce 
physicochemical changes in the corneal macromolecular matrix, and that these changes 
can be mimicked in a macromolecular matrix of plant origin as measured by changes in 
the turbidity of the assay matrix caused by alterations in protein conformation and 
structural organisation of the matrix. The degree of turbidity is proportional to the ocular 
irritation potential of the test material – as judged against positive and negative controls, 
and calibration materials. The change in matrix turbidity is measured by the light 
scattering detected by a spectrometer set to a wavelength of 405 nm and is converted to 
a numerical Irritection Draize Equivalent (IDE). The highest estimated IDE score, termed 
the Maximum Qualified Score (MQS), is then used  in the prediction model to categorise 
the ocular hazard potential of test chemicals according to the UN GHS (UN, 2015) and EU 
CLP classification systems (EC, 2008a). 
From the information available it is not clear why the changes induced in the test method 
matrix by chemicals should be specific or restricted to ocular irritants, rather than being 
also applicable to other classes of irritants (e.g. skin irritants). The supporting 
documentation claims a mechanistic basis based on the resemblance of the assay 
macromolecular matrix with the human cornea. However, in addition to the assay matrix 
never having been fully chemically characterised and not being of mammalian origin, 
there is no detailed description of the nature of the healthy human corneal matrix, or 
how it changes after exposure to ocular irritants. The documentation does not explain 
why or how the raw material was originally selected to produce the test kit 
macromolecular matrix as a surrogate for the human cornea. It also does not explain 
how the physical chemical alterations occurring in the kit matrix upon exposure to irritant 
chemicals compare to effects observed with the in vivo Draize eye test. ESAC therefore 
considers that the OI assay's mechanistic relevance to predict adverse ocular effects of 
chemicals in humans is poorly defined.  
Neither the raw materials used to produce the OI assay, nor the test kit matrix itself 
(before or after the SOP filtration step) have been chemically defined or specified. 
Furthermore, no information is available about the batch-to-batch chemical consistency 
of the raw material, as to date the manufacturer has only produced test kits from one 
batch of the plant extract.  
ESAC therefore believes that, at this stage, the assay must be considered more 
“correlative” than mechanistically relevant.  
The OI assay has a reasonably well established and defined applicability domain. It is not 
applicable to very acidic (pH < 4.0) and very alkaline (pH > 9.0) materials, oils and 
water-insoluble organic chemicals; and non-ionic surfactants can cause assay 
interference. The test method also has limitations for the testing of intensely coloured 
materials generating high OD readings for blanks and samples. In addition, volatile 
ketones have been found to result in under-estimation of irritancy due probably to 
evaporation. Finally, a number of false negatives (urea at concentrations > 5 %) and 
false positives (sorbitol at concentrations > 5 %, manganese violet, aluminium 
chlorohydrate, aluminium zirconium chlorohydrate, aluminium chloride, titanium oxide, 
zinc oxide, silver salts, ferrous sulphate, zinc sulphate) have been identified. 
The Prediction Model (PM) of the OI assay is based on that initially developed for the 
Eytex assay to predict in vivo Maximum Average Scores (MAS). In this validation study 
the previously existing MQS cut-off of 12.5 was used to distinguish classified from non-
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classified chemicals (i.e. Bottom-Up approach) and the previously existing MQS cut-off of 
30.0 was used to distinguish Category 1 from non-Category 1 chemicals (i.e. Top-Down 
approach). 
The OI assay is not intended to provide insights into persistence of chemically-induced 
ocular injuries, which could result in the underprediction of chemicals classified in vivo as 
Category 1 due only to persistence of effects if the test method is used to identify 
Category 1 chemicals, e.g., as a first step in a Top-Down approach; gases and aerosols 
were not evaluated; and the available documentation provides little information on the 
test method’s performance with mixtures. In addition, if this test method is to be used to 
identify non-irritants within an Integrated Approach to Testing and Assessment (IATA) 
then ESAC believes other test methods may be needed to assess the vascular and 
inflammatory components of the adverse outcome pathway for eye irritation, and to take 
account of the lack of epithelial barrier function.  
In addition to qualified and non-qualified runs, the submitter makes use of a third 
category, excluded runs, which impacts on the calculation of the test performance when 
comparisons are made with the reported performance of other test methods. 
For the prospective ring trial reliance was placed on a statistical power analysis (sample 
size calculation) estimating the minimum requirements for the assay’s use within a 
Bottom-Up approach (n=50). To make provision for unforeseeable events, 56 chemicals 
were used in the ring trial (five of which were subsequently excluded from the analysis of 
the test method performance). The chemicals selection was nevertheless biased in favour 
of assay use in a Bottom-Up approach. 
The predictive capacity of the OI assay as reported by the test manufacturer also took 
account of retrospective data from 45 chemicals, eight of which were also used in the 
prospective ring trial. 
The OI assay seems to be easily transferable to another laboratory with only general 
working expertise required for the lab personnel. 
In the analysis of the reliability of the assay (assessed through WLR and BLR), non-
qualified and excluded test results were considered as concordant when the three 
laboratories obtained the same outcome. 
ESAC believes that including “concordant” non-qualified and excluded test results in the 
analysis is not sound. Taking this into account, the WLR and BLR values and their 
respective Wilson two-sided 95 %-Confidence Intervals (CIs) were recalculated by ESAC 
including only qualified results (Table 1).  
 
Table 1. Calculation of WLR and BLR NOT considering consistent occurrence of "non-
qualified" and "excluded" runs as concordant in the reproducibility evaluation of the OI 
assay. The values in brackets correspond to Wilson two-side 95 %-CIs. IVI, InVitro 
International laboratory; IIVS, Institute for In Vitro Sciences laboratory; RP, Res Pharma. 
 
Within-laboratory 
Reproducibility 
Between-laboratory 
Reproducibility 
 Cut-off 12.5 Cut-off 30.0 
Cut-off 12.5 Cut-off 30.0 
 IVI IIVS RP IVI IIVS RP 
concordant predictions 45 42 41 46 43 43 42 43 
discordant predictions 6 8 10 5 7 8 8 7 
% concordance 
88.2 % 
(76.6-94.5 %) 
84.0 % 
(71.5-91.7 %) 
80.4 % 
(67.5-89.0 %) 
90.2 % 
(79.0-95.7 %) 
86.0 % 
(73.8-93.1 %) 
84.3 % 
(72.0-91.8 %) 
84.0 % 
(71.5-91.7 %) 
86.0 % 
(73.8-93.1 %) 
 
The OI reproducibility (WLR and BLR) appears to be adequate although lower than that of 
Reconstructed human Cornea-like Epithelium (RhCE)-based test methods. Nevertheless, 
since all the macromolecular matrices used in the validation study were produced from 
the same bulk plant-extract raw material (see below), it remains unknown how the 
variability of the assay may be affected by the use of different batches and suppliers of 
this raw material. 
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Predictive capacity results are summarised below (Tables 2 and 3). Due to the 
unbalanced number of repetitions between the prospective and the retrospective 
datasets available, the majority of predictions available for each chemical (mode) was 
preferred by the study Validation Management Group (VMG) as the means of expressing 
the predictive capacity of the assay. ESAC is however of the opinion that the calculations 
of Predictive Capacity should reflect in the best way possible the real-life testing 
situation. Since with the OI assay one single test result will be used to derive one final 
prediction, ESAC considers that the majority of predictions is sub-optimal to express the 
Predictive Capacity of the test method. In ESAC's opinion, more truthful point estimates 
can be obtained by using a 'weighted' calculation that considers for each chemical the 
proportion of correct classification of repeat tests or by resampling of the multiple data 
generated in the validation study. Both the weighted calculations (with two-sided 90 %-
Confidence Intervals (CIs) obtained from resampling) and predictive capacity values 
obtained from the majority of predictions (with Wilson two-sided 95 %-CIs calculated by 
ESAC) are given in Tables 2 and 3 for comparison. Published predictive capacity values 
for other serious eye/damage eye irritation in vitro methods are also provided for 
comparison. 
When used for the identification of UN GHS non-classified versus classified materials 
(based on the existing cut-off of 12.5) the OI assay showed an overall sensitivity of 90.7 
% (two-sided 90 %-CIs: 87.0 % and 93.5 %), a specificity of 58.9 % (two-sided 90 %-
CIs: 53.5 % and 65.1 %) and an overall accuracy of 75.3 %, based on weighted 
calculations (Table 2). Some organic functional groups were found possibly to correlate 
with the observed mispredictions. In particular, acrylate, carboxamide, and cycloalkenes. 
If, despite their small number, chemicals containing these functional groups were 
excluded from analyses, the obtained dataset resulted in a sufficiently large dataset 
(n=79) to still derive sound conclusions. Such findings are comparable to the currently 
accepted OECD test methods as shown in Table 2.  
 
Table 2. Predictive capacity of the OI for the identification of UN GHS/EU CLP non-
classified chemicals and comparison to published values for other in vitro methods. 
  
 
OI 
n=88 
weighted 
(resampling 
90 %-CI) 
OI* 
n=79 
weighted 
(resampling 
90 %-CI) 
OI 
n=88 
majority of 
predictions 
(Wilson 
95 %-CI) 
OI* 
n=79 
majority of 
predictions 
(Wilson 
95 %-CI) 
BCOP  
(TG437) 
n=196 
majority of 
predictions 
ICE  
(TG 438) 
n=152 
majority of 
predictions 
STE** 
 (TG 491) 
n=101 
EpiOcular 
EIT  
(TG 492) 
n=112 
weighted 
CM*** 
 (Draft TG) 
n=45 
weighted 
Accuracy 
75.3 % 
n.a. 
80.5 % 
n.a. 
76.1 %  
(67/88) 
(66.3-83.8 %) 
81.0 %  
(64/79) 
(71.0-88.1 %) 
68.9 %  
(135/196) 
82.2 %  
(125/152) 
90.1 %  
(91/101) 
80 %  
(n=112) 
68 %  
(n=45) 
Sensitivity 
90.7 % 
(87.0-93.5 %) 
96.4 % 
(92.9-100 %) 
93.3 %  
(42/45) 
(82.1-97.7 %) 
97.6 %  
(40/41) 
(87.4-99.6 %) 
100.0 %  
(107/107) 
98.6 %  
(72/73) 
98.1 %  
(53/54) 
96 %  
(n=57) 
100 %  
(n=22) 
Specificity 
58.9% 
(53.5-65.1 %) 
62.8 % 
(55.3-71.1%) 
58.1 %  
(25/43) 
(43.3-71.6 %) 
63.2 %  
(24/38) 
(47.3-76.6 %) 
31.5 %  
(28/89) 
67.1 %  
(53/79) 
80.9 % 
(38/47) 
63 %  
(n=55) 
32 %  
(n=23) 
*excludes chemicals containing the acrylate, carboxamide and cycloalkenes organic functional groups. 
** Only water-soluble chemicals or chemicals forming a uniform suspension, and excluding highly volatile 
substances and solid substances other than surfactants; 
*** Only water-soluble surfactants and surfactant-containing formulations 
 
For the identification of the UN GHS /EU CLP Category 1 chemicals a post-hoc evaluation 
of the entire dataset comprising both, the prospective validation dataset and the 
additional existing data from retrospective studies was carried out. When used for the 
identification of UN GHS Category 1 versus non-Category 1 chemicals (based on the cut-
off of 30.0) the OI assay showed an overall specificity of 80.9 % (two-sided 90 %-CIs: 
76.8 % and 84.1 %), a sensitivity of 53.3 % (two-sided 90 %-CIs: 50.0 % and 60.0 %), 
and an accuracy of 74.7 %, based on weighted calculations (Table 3). These values are 
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compared with those of the currently accepted OECD in vitro test methods for eye hazard 
assessment in Table 3 below.  
Further investigations conducted by the VMG to better understand possible reasons for 
misclassification suggested that chemicals having the presence of the organic functional 
groups carboxylic acid and sulphate seemed to risk possible underpredictions of Category 
1 chemicals as non-Category 1 chemicals. Excluding chemicals having these functional 
groups from analyses resulted still in a sufficiently large dataset to make sound 
conclusions (n=74). In this case, a specificity of 80.0 % (48/60), a sensitivity of 71.4 % 
(10/14) and a concordance of 78.4 % (58/74) were obtained, based on the majority of 
predictions. 
 
Table 3. Predictive capacity of the OI for the identification of UN GHS / EU CLP Category 
1 chemicals and comparison to published values for other in vitro methods. 
  
OI 
n=88 
weighted 
(resampling 90 %-CI) 
OI 
n=88 
majority of 
predictions 
(Wilson 95 %-CI) 
BCOP 
(TG 437) 
n=191 
majority of 
predictions  
ICE 
(TG 438) 
n=140 
majority of 
predictions  
FL 
(TG 460)  
n=151 
weighted 
STE 
(TG 491) 
n=120* 
CM 
(Draft TG) 
n=68* 
weighted 
Accuracy 
74.7 % 
n.a. 
73.9 %  
(65/88) 
(63.8-81.9 %) 
78.5 %  
(150/191) 
85.7 %  
(120/140) 
77.5 %  
(117/151) 
85.0 %  
(102/120) 
88 %  
(n=68) 
Specificity 
80.9 % 
(76.8-84.1 %) 
80.9 %  
(55/68) 
(70.0-88.5 %) 
74.6 %  
(94/126) 
93.8 %  
(106/113) 
93.2 %  
(96/103) 
98.8 %  
(83/84) 
98 %  
(n=42) 
Sensitivity 
53.3 % 
(50.0-60.0 %) 
50.0 %  
(10/20) 
(29.9-70.1 %) 
86.2 %  
(56/65) 
51.9 %  
(14/27) 
43.8 % 
 (21/48) 
52.8 %  
(19/36) 
73 %  
(n=26) 
* water-soluble chemicals or chemicals forming a uniform suspension. 
 
Overall the rationale provided for the assay limitations with respect to the applicability of 
the OI assay to particular types of chemicals is weak since the exclusion of chemicals is 
based on single or a very limited number of representative chemicals. 
When used to identify Category 1 chemicals (e.g., as a first step in a Top-Down 
Approach), the OI assay shows rather low sensitivity (influenced in part by its limitation 
to detect persistence of effects as mentioned above) and only moderate specificity. Thus, 
other than having a long shelf-life and short testing time, the OI assay does not seem to 
be an advance on other validated test methods for this purpose. 
Whilst the performance of the test method for identifying non-classified chemicals 
appears to be adequate, there are a number of uncertainties related with the method 
that may call into question its regulatory acceptance, not least a lack of control over the 
precise chemical composition, stability and structure of the test matrix (to date only 
produced from one batch of the plant-extract over a period of 25+ years); the unknown 
variability of the method if performed with matrices produced from different bulks of the 
plant-extract raw material (to date only matrices produced from a single bulk have been 
evaluated), and a lack of transparency about the details of the software used in the OI 
assay to analyse the data. On this basis, ESAC is also not able to offer a reasoned 
opinion on what might constitute Essential Test Method Components for any assay of this 
class to be included in Performance Standards: it is not clear how an essential test 
method component can be defined without specifying the test matrix origin and its 
chemical composition.  
ESAC also notes that the Performance Standards provided for peer review are incomplete 
as they lack a list of reference chemicals and target values for reproducibility and 
predictive capacity. The chemicals used in the validation study of the OI assay would be 
suitable only for similar test methods with the same precise applicability domain.  
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On the basis of the above, ESAC does not recommend the use of the OI assay for 
regulatory testing purposes. Nevertheless, considering that (i) the assay is relatively easy 
and fast to perform, (ii) its performance appears to be acceptable, (iii) it is easily shipped 
and stored, and (iv) it has a long shelf-life, ESAC considers that the assay may be useful 
for screening purposes within the applicability domain established in the SOP. Users of 
the OI assay should nevertheless take into consideration that the applicability domain of 
the method has been imperfectly defined, being purely empirical and not biologically 
justified.   
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1. TYPE OF REQUEST 
Request Type Identify request ("YES") 
R1 ESAC Peer Review  
of a Prevalidation Study or Validation Study 
YES, external validation study  
(i.e. not coordinated by EURL ECVAM) 
If R1)applies please specify further: 
►Prevalidation Study NO 
►Prospective Validation Study YES (the submission includes a prospective validation 
study with 56 test chemicals as well as retrospective 
data on an additional 45 test chemicals, for a total of 
93 unique chemicals) 
 
Background 
The Ocular Irritection® is an in vitro macromolecular test 
method, representing a refinement of the former Eytex® 
method (Kelly, 1989; Gordon, 1992) following 
recommendations made by Balls et al. (1995). 
It intends to predict the ocular hazard effects of chemicals 
based on the premise that corneal opacity may result from 
the disruptive effects ocular irritants may have on the highly 
organised structure of the cornea through interaction with 
some of its components (e.g. proteins and carbohydrates). 
This assay thus mimics the biochemical phenomena of 
corneal protein denaturation and disruption caused by 
irritant chemicals acting on the cornea. The test method 
uses as test system a  macromolecular matrix composed of 
a mixture of plant proteins, plant glycoproteins, plant 
carbohydrates, plant lipids and low molecular weight plant 
components, which mimics the highly ordered structure of 
the transparent cornea.  
The Ocular Irritection® underwent an external prospective 
and retrospective validation study to assess its usefulness 
and limitations to identify chemicals not requiring 
classification for serious eye damage/eye irritation ('No 
Category') and chemicals inducing serious eye damage 
('Category 1'), according to the United Nations Globally 
Harmonized System of Classification and Labelling of 
Chemicals (UN GHS) (UN, 2015) and the European Union 
Regulation on Classification, Labelling and Packaging of 
chemicals (EU CLP) (EC, 2008), in the framework of a 
Bottom-Up/Top-Down testing strategy (Scott et al., 2010). 
In December 2013, after completion of the validation study, 
EURL ECVAM received a full submission on the Ocular 
Irritection® test method. EURL ECVAM evaluated the 
submission and concluded that the test method appears to 
be promising as a partial replacement to identify 
'Category 1' and 'No Category' chemicals. However, EURL 
ECVAM noted a number of shortcomings in the method 
definition and in the information provided concerning its 
performance (reproducibility and predictive capacity) and, 
in August 2014, the test submitter was requested to 
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address and clarify these issues in a revised submission. 
Upon request of the test submitter, a meeting between 
EURL ECVAM and the Validation Management Group (VMG) 
of the Ocular Irritection® validation study was organised in 
October 2014 to discuss the various points raised by EURL 
ECVAM in its assessment report. Following this meeting, the 
submitter updated its submission with additional (non-
testing) information and further biostatistical analyses as 
requested by EURL ECVAM, and provided a full revised 
submission in April 2015. EURL ECVAM evaluated this 
revised submission, and the updated assessment report is 
made available to the ESAC in the accompanying documents 
of the current request.  
►Retrospective Validation Study YES (see above) 
►Validation Study based on Performance 
Standards 
NO 
R2 Scientific Advice on a test method submitted to 
EURL ECVAM for validation  
(e.g. the test method's biological relevance etc.) 
NO 
R3 Other Scientific Advice  
(e.g. on test methods, their use; on technical issues such as cell 
culturing, stem cells, definition of performance standards etc.) 
NO 
 
 
2. TITLE OF STUDY OR PROJECT FOR WHICH SCIENTIFIC ADVICE OF THE 
ESAC IS REQUESTED 
External prospective and retrospective validation of the in vitro Ocular Irritection® (OI) test 
method for prediction of serious eye damage/eye irritation potential of chemicals 
 
 
3. BRIEF DESCRIPTION OF THE STUDY OR PROJECT 
3.1. Background on serious eye damage/eye irritation and current testing strategies 
3.1.1. Serious eye damage/eye irritation 
Serious eye damage/eye irritation is an adverse effect that produces changes in the eye following 
exposure of the anterior surface of the eye to a test substance. According to UN GHS (UN, 2015), 
serious eye damage is the production of tissue damage in the eye, or serious physical decay of vision, 
following application of a test substance to the anterior surface of the eye, which is not fully 
reversible within 21 days of application. Eye irritation is the production of changes in the eye 
following the application of a test substance to the anterior surface of the eye, which are fully 
reversible within 21 days of application.  
UN GHS includes three main categories for the classification of chemicals: Category 1 (abbr. Cat 1) for 
"serious eye damage", Category 2 (abbr. Cat 2) for "eye irritation" and No Category (abbr. No Cat) for 
"not-classified". 
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Currently, serious eye damage/eye irritation can be determined through in vivo and in vitro assays. 
The traditional in vivo test is the Draize eye test, which uses rabbits as model for ocular toxicity 
(OECD Test Guideline (TG) 405) (OECD, 2012a). Validated in vitro alternative methods are available 
based on organotypic assays (Bovine Corneal Opacity and Permeability test, Isolated Chicken Eye 
test), adopted in 2009 and revised in 2013 (TG 437, TG 438) (OECD, 2013a, b), on cell-based assays 
(Fluorescein Leakage, Short Time Exposure and Cytosensor Microphysiometer) adopted in 2012 (TG 
460) (OECD, 2012b) and in 2015 (TG 491) (OECD, 2015a) or currently undergoing regulatory 
acceptance (draft TG on the Cytosensor Microphysiometer), and on Reconstructed human Cornea-
like Epithelium (EpiOcular™ EIT) adopted in 2015 (TG 492) (OECD, 2015b). 
 
3.1.2. Testing strategies composed of in vitro methods 
It is generally accepted that, in the foreseeable future, no single in vitro test method will be able to 
replace the in vivo Draize eye test (TG 405) (OECD, 2012a) in its capacity to predict averse ocular 
effects for the full range of potency and for a broad spectrum of chemical classes (wide applicability 
domain). However, appropriate combinations of several alternative test methods within (tiered) 
testing strategies may be able to replace the Draize eye test.  
A possible conceptual framework for such (tiered) testing strategies was developed within an EURL 
ECVAM workshop (Scott et al., 2010). The framework is based on alternative serious eye damage/eye 
irritation methods that vary in their capacity to detect chemicals inducing serious eye damage (Cat 1) 
and/or chemicals not requiring classification for serious eye damage/eye irritation (No Cat). 
According to this framework, the entire potency range of effects may be resolved by arranging tests 
in a tiered (sequential) strategy that may be operated bidirectional, i.e. from either end. As such, the 
strategy intends to classify chemicals following two possible types of approaches colloquially referred 
to as 'Top-Down' and 'Bottom-Up' (Scott et al., 2010). In the Top-Down approach, the testing aims to 
first identify Cat 1 chemicals, discriminating these from the rest, i.e. a combination of Cat 2 and No 
Cat chemicals. Conversely, in the Bottom-Up approach, the testing aims to first identify No Cat 
chemicals, discriminating these from all chemicals requiring classification, i.e. Cat 1 and Cat 2 
chemicals combined. Ocular irritant chemicals (Cat 2) will be resolved in a last tier in both 
approaches.  
In the international regulatory context, this framework is established within an Integrated Approach 
to Testing and Assessment (IATA), which is currently under development at the OECD. The IATA 
includes several modules considering already existing data, physicochemical properties, (Q)SARs and 
other in silico tools and empirical testing tools (including in vitro methods and, as a last resource, in 
vivo testing). The IATA integrates the use of the Top-Down and Bottom-Up approaches when 
generation of new testing data is necessary i.e., if no conclusion can be drawn from existing and in 
silico data. In the European regulatory context, the ECHA Guidance on Information Requirements and 
Chemical Safety Assessment (IR&CSA), Chapter R.7a: Endpoint specific guidance, provides guidance 
on the integration of testing and non-testing data for the assessment of eye damage/irritation and is 
regularly updated (ECHA, 2015). 
 
3.2. Background on the Ocular Irritection® test method 
The Ocular Irritection® (OI) is a test method that uses as test system a macromolecular matrix of plan 
origin intending to mimic the highly organised structure of the transparent cornea. The topical 
application of irritant substances induces changes of the matrix (turbidity) which are measured by 
optical density. The increase in optical density is used to predict the ocular hazard effects of 
chemicals based on the premise that corneal opacity observed in vivo may result from the disruptive 
effects ocular irritants may have on the highly organised structure of the cornea through interaction 
with some of its components (e.g. proteins and carbohydrates).  
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3.2.1. Study objectives and design 
The OI aims to identify both No Cat and Cat 1 chemicals in the framework of a Bottom-Up/Top-Down 
testing strategy. It is not intended to identify Cat 2 chemicals on its own. The OI underwent an 
external prospective and retrospective validation study. The goal of the study was initially to assess 
the relevance (predictive capacity), reliability (transferability and reproducibility within and between 
laboratories) and limitations/applicability domain of the OI to identify No Cat chemicals. A post-hoc 
evaluation of the OI to identify Cat 1 chemicals was however also conducted. 
The submission of the OI external validation study comprises both retrospective and prospective 
data. In the prospective part of the validation study 56 chemicals with existing reference in vivo 
Draize eye test data were tested in a ring trial involving three laboratories, of which 4 chemicals 
provided "excluded" data in all tests in all laboratories. The prospective data were used to evaluate 
the reproducibility (within- and between-laboratories), predictive capacity (sensitivity, specificity and 
accuracy) and limitations/applicability domain of the OI for the purposes of identifying No Cat 
(Bottom-Up) or Cat 1 (Top-Down) chemicals. The assessment of the OI predictive capacity and 
limitations was also complemented with retrospective in vitro data available for 45 unique chemicals 
that had been generated with the same protocol as the one used in the prospective validation study. 
Out of these 45 chemicals, 37 were in addition to the prospective validation dataset and 8 were also 
tested in the prospective validation study. 
If found valid for its proposed uses, the OI may be formally incorporated into an OECD Test Guideline 
(it is currently already included in the OECD work programme under the leadership of Italy). 
Additionally, the OI may also be incorporated in the draft IATA currently under development at the 
OECD.   
 
3.2.2. Summary of study results  
The study results are presented in detail in the test submission and the EURL ECVAM assessment 
report. They are also summarised in the following paragraphs. 
 
(a) Within- and between laboratory reproducibility (WLR and BLR) 
The submitter and EURL ECVAM had slightly different views on the data that should be used to 
calculate within- and between laboratory reproducibility (WLR and BLR). The submitter and the VMG 
deemed that consistent occurrence of "non-qualified"/"excluded" runs could be considered as 
concordant. In contrast, EURL ECVAM recommended that the submitter discards "non-
qualified"/"excluded" runs from the calculations of reproducibility. However, the impact in terms of 
differences between these two views is limited (<2%) as indicated in the table below provided by the 
test submitter. 
 
 
WLR and BLR assessment provided by the submitter 
Calculation of WLR (and BLR) when considering consistent occurrence of "non-qualified" and 
"excluded" runs as concordant in the reproducibility evaluation of the OI assay 
  
Within-laboratory Between-laboratory 
 Cut-off 12.5 
(identification of No Cat) 
Cut-off 30.0 
(identification of Cat 1) 
Cut-off 12.5 
(identification of 
No Cat) 
Cut-off 30.0 
(identification of 
Cat 1) 
 
IVI IIVS RP IVI IIVS RP 
concordant predictions 45 42 41 46 43 43 42 43 
discordant predictions 6 8 11 5 7 8 10 9 
concordant excluded 4 5 4 4 5 4 4 4 
concordant NQ 1 1 0 1 1 0 0 0 
overall concordant 50 48 45 51 49 46 46 47 
% concordance 89.3 85.7 80.4 91.1 87.5 83.9 82.1 83.9 
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Calculation of WLR and BLR when EURL ECVAM's suggestions are taken up i.e., NOT considering 
consistent occurrence of "non-qualified" and "excluded" runs as concordant in the reproducibility 
evaluation of the OI assay 
 
Within-laboratory Between-laboratory 
 Cut-off 12.5 
(identification of No Cat) 
Cut-off 30.0 
(identification of Cat 1) 
Cut-off 12.5 
(identification of 
No Cat) 
Cut-off 30.0 
(identification of 
Cat 1) 
 
IVI IIVS RP IVI IIVS RP 
concordant predictions 45 42 41 46 43 43 42 43 
discordant predictions 6 8 11 5 7 8 10 9 
% concordance 88.2 84.0 78.8a 90.2 86.0 84.3 80.8b 82.7c 
a
 The value calculated by EURL ECVAM corresponds to 80.4% (41/51) 
b
 The value calculated by EURL ECVAM corresponds to 84.0% (42/50) 
c
 The value calculated by EURL ECVAM corresponds to 86.0% (43/50) 
 
(b) Predictive capacity 
According to EURL ECVAM on the basis of weighted calculations, the results are the following: 
 
 Prospective validation data considering chemicals with qualified data in at least one 
laboratory (n=52) 
 
Prospective validation data: Evaluation of the OI predictive capacity for both top-down and bottom-up approaches 
using a weighted calculation 
Predictive Capacity TOP-DOWN BOTTOM-UP 
Sensitivity 
42.4% 
(4.67/11) 
87.4% 
(20.11/23) 
False Negatives 
57.6% 
(6.33/11) 
12.6% 
(2.89/23) 
Specificity 
80.2% 
(32.89/41) 
55.6% 
(16.11/29) 
False Positives 
19.8% 
(8.11/41) 
44.4% 
(12.89/29) 
Overall Accuracy 
72.2% 
(37.56/52) 
69.7% 
(36.22/52) 
Total Mispredictions 
27.8% 
(14.44/52) 
30.3% 
(15.78/52) 
 
 Combined prospective and retrospective validation data considering chemicals with qualified 
data in at least one laboratory (n=89) 
 
Combined prospective and retrospective validation data: Evaluation of the OI predictive for both top-down and bottom-
up approaches using a weighted calculation 
Predictive Capacity TOP-DOWN BOTTOM-UP 
Sensitivity 
53.4% 
(10.67/20) 
90.7% 
(41.71/46) 
False Negatives 
46.7% 
(9.33/20) 
9.3% 
(4.29/46) 
Specificity 
81.0% 
(55.89/69) 
59.8% 
(25.71/43) 
False Positives 
19.0% 
(13.11/69) 
40.2% 
(17.29/43) 
Overall Accuracy 
74.8% 
(66.56/89) 
75.8% 
(67.42/89) 
Total Mispredictions 
25.2% 
(22.44/89) 
24.2% 
(21.58/89) 
 
Additionally, the submitter followed EURL ECVAM suggestion and provided results after resampling, 
for both bottom-up and top-down approach, for the combined prospective and retrospective 
validation data: 
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Predictive capacity for the bottom-up approach, calculated by the submitter following resampling. The * sign means 
including chemical #23. The reduced applicability domain excludes acrylate, carboxamide and cycloalkenes functional 
groups 
 Bottom-up (n=88 or 89* chemicals) Bottom-up for a reduced applicability domain suggested by 
the submitter (n=79 or 80* chemicals) 
 Resampling 
5%-quantile 
(n=43+45) 
Point 
estimate:  
mode of 
repeat 
tests 
Point 
estimate: 
weighted 
Resampling 
95%-
quantile 
(n=43+45) 
Resampling 
5%-quantile 
(n=38+41) 
Point 
estimate: 
mode of 
repeat 
tests 
Point 
estimate: 
weighted 
Resampling 
95%-quantile 
(n=38+41) 
Specificity 53.5% 58.1% 
(25/43) 
58.9% 
(25.31/43) 
65.1% 55.3% 63.2% 
(24/38) 
62.8% 
(23.88/38) 
71.1% 
Sensitivity 87.0% 93.3% 
(42/45) 
90.7% * 
(41.71/46) 
93.5% 92.9% 97.6% 
(40/41) 
96.4% * 
(40.49/42)  
100% 
Accuracy na 76.1% 
(67/88) 
75.3% 
(67.02/89) 
na na 81.0% 
(64/79) 
80.5% 
(64.37/80) 
na 
 
The reduced applicability domain that was proposed by the submitter was concluded on the basis of 
an OECD QSAR Toolbox analysis of organic functional groups (OFG) and correlation of these with 
false predictions. However, according to EURL ECVAM, the evaluation of predictive capacity for this 
reduced applicability domain cannot be considered robust enough as some of the limitations (e.g., 
acrylates) were assumed on the basis of a single chemical representing that particular OFG being 
tested. 
 
Predictive capacity for the top-down approach, calculated by the submitter following resampling approach. The * sign 
means including chemical #23 
 Top-down (n=88 or 89* chemicals) 
 Resampling 5%-quantile 
(n=68+20) 
Point  estimate:  
mode of repeat tests 
Point estimate: weighted Resampling 95%-
quantile 
(n=68+20) 
Specificity 76.8% 80.9% 
(55/68) 
80.9% 
(55.81/69) 
84.1% 
Sensitivity 50.0% 50.0% 
(10/20) 
53.3% 
(10.67/20) 
60.0% 
Accuracy na 73.9% 
(65/88) 
74.7% 
(66.48/89) 
na 
 
Finally, also ROC analyses were performed upon the suggestion of EURL ECVAM to obtain a better 
picture of the overall performance of the OI assay in the prospective study: 
 
ROC analysis and areas under ROC curves (AUROC) using data from the prospective validation study. Left part: 
submitter's input in its revised submission; Right part: EURL ECVAM's analysis 
 Submitter's ROC analysis EURL ECVAM's ROC analysis 
 Bottom-Up Approach Top-Down Approach Bottom-Up Approach Top-Down Approach 
n AUROC n AUROC n AUROC n AUROC 
IVI 51 0.7813 51 0.6977 51 0.8017 51 0.6890 
IIVS 50 0.8263 50 0.7366 50 0.8523 50 0.7362 
RP 51 0.7915 51 0.7136 51 0.8009 51 0.7061 
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4. OBJECTIVES, QUESTIONS, TIMELINES 
4.1  OBJECTIVE 
Objective 
Why does EURL 
ECVAM require 
advice on the 
current issue? 
EURL ECVAM requests an ESAC opinion on the reliability (reproducibility within and 
between laboratories of results obtained in vitro) and relevance (predictive capacity of 
effects documented in vivo) of the Ocular Irritection® test method for prediction of 
eye irritation potential of chemicals. The opinion of ESAC should support EURL 
ECVAM with respect to the possible development of an EURL ECVAM 
recommendation on the Ocular Irritection® for serious eye damage/eye 
irritation testing outlining (1) the scientific basis of the assay, (2) its overall 
performance (transferability, reproducibility and predictive capacity) as assessed 
during the validation study and based on other (e.g. published) information, (3) 
its applicability and limitations, and 4) its proposed use. 
ESAC's advice should enable a conclusion on the potential adequacy of the 
Ocular Irritection® for routine testing of serious eye damage/eye irritation for 
regulatory purposes. 
 
 
 
4.2  QUESTION(S) TO BE ADDRESSED 
Questions 
What are the 
questions and 
issues that should 
be addressed in 
view of achieving 
the objective of 
the advice? 
The ESAC peer review of the Ocular Irritection® should address the following 
aspects: 
(1) Scientific basis in relation to serious eye damage/eye irritation. 
(2) Clarity of the test definition, including: 
- purpose and need of the test method. 
- biological/mechanistic relevance in relation to the test system used and the 
endpoint measured. 
- protocol clarity and completeness. 
- clarity and adequacy of the prediction model and its development. 
(3) Clarity of the definition of the study objective(s). 
(4) Appropriateness of the study design and execution considering the study 
objective(s), including: 
- number and selection criteria for test chemicals (e.g., range of 
documented effects in vivo, etc.). 
- quality assurance of reference data (in vivo) for predictive capacity 
assessment. 
- number of participating laboratories. 
- number of replicates, number of repetitions, rules for retesting and 
handling of deviations. 
(5) Study management and conduct. 
(6) Results compilation and statistical analyses reporting, including: 
- appropriateness of calculation of WLR and BLR on the basis of the 
generated data. 
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- appropriateness of calculation of Predictive Capacity on the basis of the 
generated data. 
- appropriateness of identification of limitations/applicability domain on the 
basis of the generated data. 
(7) Transferability and reproducibility (WLR/BLR). 
(8) Predictive capacity and relevance to a tiered (Top-Down/Bottom-Up) 
testing strategy when used for: 
- distinguishing chemicals not requiring classification from chemicals 
requiring classification as Category 1 (serious eye damage) or Category 2 (eye 
irritation). 
- distinguishing chemicals requiring classification as Category 1 (serious eye 
damage) from chemicals not requiring classification as Category 1 (i.e. 
Category 2 (eye irritation) or No Category (not classified)). 
(9) Applicability and any known limitations, assessed from the selection of 
the test chemicals (range of molecular class and physical properties) and 
analyses of possible reasons for misclassifications. 
(10) Completeness and adequacy of the Performance Standards proposed by 
the submitter, including the Essential Test Method Components, the list of 
Reference Chemicals and the Target Values for Reproducibility and Predictive 
Capacity. 
(11) Possible gaps, if any, between study design and study conclusions. 
(12) Whether the information provided in the submission is sufficient to 
substantiate the proposed use of the test method within a Bottom-Up/Top-
Down testing strategy. 
(13) What additional work, if necessary, should be undertaken in future to 
further characterise the test method and its proposed use. 
ESAC's advice should conclude on the regulatory applicability of the Ocular 
Irritection® (i.e., for implementation as an EU test method and OECD Test 
Guideline). 
 
 
 
 
4.3  TIMELINES 
Timelines 
concerning this 
request 
When does EURL 
ECVAM require 
the advice? 
Timeline Indication 
Finalised ESAC Opinion required by: June 2016 
Request to be presented to ESAC by 
written procedure (e.g. due to 
urgency) prior to the next ESAC 
YES 
Request to be presented to ESAC at 
ESAC plenary meeting 
NO 
 
 
EURL ECVAM REQUEST FOR ESAC ADVICE  Page | 23 
5.  EURL ECVAM PROPOSALS ON HOW TO ADDRESS THE REQUEST WITHIN 
ESAC 
5.1  EURL ECVAM PROPOSAL REGARDING REQUEST-RELATED STRUCTURES REQUIRED 
Specific 
structures 
required within 
ESAC to address 
the request 
Does the advice 
require an ESAC 
working group, an 
ESAC rapporteur 
etc.? 
Structure(s) required Required according to EURL ECVAM? 
(YES/NO) 
S1 ESAC Rapporteur NO 
S2 ESAC Working Group 
ESAC members 
- José M. Navas (Chair) 
- Kristina Kejlová 
- Annete Kopp-Schneider 
- Renate Kraetke 
- Jon Richmond 
ICATM nominations 
- Dave Allen (NICEATM/ICCVAM) 
- Kyung-Min Lim (College of Pharmacy, 
Ewha Womans University; nominated 
by KoCVAM) 
S3 Invited Experts NO 
Ad S3: If yes – list names and 
affiliations of suggested 
experts to be invited and 
specify whether these are 
member of the EEP 
 
If other than above (S1-S3):   
 
5.2  DELIVERABLES AS PROPOSED BY EURL ECVAM 
Deliverables 
What deliverables 
(other than the 
ESAC opinion) are 
required for 
addressing the 
request? 
Title of deliverable other 
than ESAC opinion 
Required? (YES/NO) 
D1 ESAC Rapporteur Report 
and draft opinion  
NO 
D2 ESAC Working Group 
Report and draft opinion 
YES 
If other than above (D1-D2):  
EURL ECVAM REQUEST FOR ESAC ADVICE  Page | 24 
6. LIST OF DOCUMENTS TO BE MADE AVAILABLE TO THE ESAC 
 
Count Description of document Already 
available? 
(YES/NO) 
File name 
1 Ocular Irritection® test 
submission (TST) (latest version 
submitted to EURL ECVAM - 
clean) 
Yes 1a_TST_OI_assay_30_12_2013_Rev10April2015_cl
eared.pdf 
2 Ocular Irritection® test 
submission (TST) (latest version 
submitted to EURL ECVAM – 
with tracked changes) 
Yes 1b_TST_OI_assay_30_12_2013_Rev10April2015_T
C(vs. v.30Dec2013).docx 
3 Letter from test method 
submitter summarising the 
main amendments made in the 
latest revised version of  the 
Ocular Irritection® test 
submission 
Yes 0a_AccompanyingLetter_OI_TST_finalSubmission_
10April2015.pdf 
4 Attestation letter from test 
method submitter clarifying the 
roles of each party in the 
submission 
Yes 0b_AttestationLetter_8April2015.pdf 
5 EURL ECVAM assessment report 
on the Ocular Irritection® test 
submission (updated version 
considering the last revised 
submission) 
Yes Ocular_Irritection_updated_assessment_report_2
016-05-09_final.pdf  
6 Standard Operating Procedure 
(SOP) of the Ocular Irritection® 
Yes 1_Att1a_SOP_OI.pdf 
7 DB-ALM protocol n. 157 Yes 2a_Att1b_DBAlm157_OI.pdf 
8 Details of kit components, 
software setup, data 
calculation, and example of an 
OI assay report (CONFIDENTIAL) 
Not on 
CIRCABC 
(provided by 
e-mail only) 
2b_Att1c_CONFIDENTIAL_KitComp_SoftSetup_Dat
aCalc_ExplOIReport_NEW_15Oct2014.pdf 
9 Interpretation of Ocular 
Irritection® data 
(CONFIDENTIAL) 
Not on 
CIRCABC 
(provided by 
e-mail only) 
2c_Att1d_CONFIDENTIAL_InterpOIData_NEW_15O
ct2014.pdf 
10 Quality Audit Report Yes 3a_Att1e_IVI_Quality_Audit.pdf 
11 Quality Audit Questionnaire Yes 3b_Att1e_IVI_Quality_Audit_Questionnaire.pdf 
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12 Identity and characteristics of 
the 56 chemicals tested in the 
prospective validation study 
(WLR, BLR) 
Yes 4_Att3_ID_ProspChem_WLR_BLR.pdf 
13 WLR and BLR results Yes 5_Att4_WLV_and_BLV_Results_rev8April2015.pdf 
14 Transferability test items and 
results 
Yes 6_Att5_Transf_Results.pdf 
15 Training and transferability 
report 
Yes 7_Att6_Train_Transf_Report.pdf 
16 Identity and characteristics of 
the chemicals tested in the 
prospective and retrospective 
validation study (PC) 
Yes 8_Att11_ID_Prosp_Retrosp_Chem_PC.pdf 
17 Predictive Capacity results Yes 9a_Att12a_PC_Results_rev29March2015.pdf 
18 MSDS of chemical n. 12, 
Tetraethylene glycol diacrylate, 
CAS 17831-71-9 
Yes 9b_Att12b_MSDS_Chemical12_Tetraethylene 
glycol diacrylate_NEW_8April2015.pdf 
19 Results of the evaluation on 
possible reasons for 
misclassification 
Yes 9c_Att12c_ReasonsMissclassification_Rev8April20
15.pdf 
20 Project plan(s) Yes 10_Att13_Project 
Plan_8March2011_Rev8April2015.pdf 
21 Overview of test items used in 
the validation study 
Yes 11_Att14_Overview_Chem_VS.pdf 
22 Draft Performance Standards 
for validation of a similar or 
updated test method 
Yes 12_Att16_DraftPerfStand_OI_NEW_10April2015.d
ocx 
23 Peer-reviewed publication of 
the validation study and its 
outcomes 
Yes 13_Att17a_Eskesetal_OIValidation_TIV_2014_NE
W_10April2015.pdf 
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7. TERMS OF REFERENCE OF THE ESAC WORKING GROUP 
7.1 ESTABLISHMENT OF THE ESAC WORKING GROUP 
The ESAC unanimously agreed by written procedure on the 18th of February 2016 on the composition 
of a new ESAC Working Group for the review of test methods in the area of serious eye damage/eye 
irritation. 
 
7.2 TITLE OF THE ESAC WORKING GROUP 
Full title:  
ESAC Working Group on Eye Irritation Test Methods 
 
Abbreviated title:  
ESAC WG Eye Irritation 
 
7.3 MANDATE OF THE ESAC WORKING GROUP 
The EWG is requested to conduct a scientific review of the Ocular Irritection® validation study.. The 
review needs to address the questions put forward to ESAC by EURL ECVAM under section 4.2 of the 
current request. 
The review should focus on the appropriateness of design and conduct of the study in view of the 
study objective and should provide an appraisal to which extent the conclusions of the test submitter 
are substantiated by the information generated during the study and how the information generated 
relates to the scientific background available. 
 
7.4 DELIVERABLES OF THE ESAC WORKING GROUP 
The ESAC WG is requested to deliver to the chair of the ESAC and the ESAC Coordinator a detailed 
ESAC Working Group Report outlining its analyses and conclusions and a draft ESAC Opinion. A 
template has been appended (Appendix 1) intended to facilitate the drafting of the WG report. 
The conclusions drawn in the report should be based preferably on consensus. If no consensus can 
be achieved, the report should clearly outline the differences in the appraisals and provide 
appropriate scientific justifications. 
 
7.5 PROPOSED TIMELINES OF THE ESAC WORKING GROUP 
Item Proposed date/time Action Deliverable 
1 6 May 2016 Teleconference of the Working 
Group 
Agree procedure 
2 11-13 May 2016 Working Group meeting  Draft ESAC WG report and draft 
ESAC opinion 
3 27 May 2016 Circulation of final WG report and 
draft ESAC opinion to ESAC 
Final draft ESAC WG report and 
draft ESAC opinion 
4 9-10 June 2016 Endorsement of WG report and 
ESAC opinion at ESAC42 meeting 
Final ESAC WG report and ESAC 
opinion 
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7.6 QUESTIONS WHICH SHOULD BE ADDRESSED BY THE ESAC WORKING GROUP 
The review should address the questions put forward to ESAC by EURL ECVAM (see section 4.2) and 
the information requirements of the ESAC Working Group Template, where applicable. The ESAC 
Coordinator will provide guidance if needed. 
When preparing the final ESAC WG report to address these questions, the ESAC WG is requested to 
use a pre-defined reporting template. This template (see appendix 1) follows EURL ECVAM's modular 
approach and addresses to which extent the standard information requirements have been 
addressed by the study. The template allows moreover for addressing the issues specific studies 
outlined in section 4.2. The Secretariat will provide guidance if necessary. 
 
 
APPENDIX 1  REPORTING TEMPLATE 
The appended ESAC WG template suggests a structure that is in close agreement with the EURL 
ECVAM information requirements ("modules") for scientific review following validation and allows at 
the same time for the description of the analysis and conclusions concerning more specific questions.  
 
The template can be used for various types of validation studies (e.g. prospective full studies, 
retrospective studies, performance-based studies and prevalidation studies). Depending on the study 
type and the objective of the study, not all sections may be applicable.  
 
However, for reasons of consistency and to clearly identify which information requirements have not 
been sufficiently addressed by a specific study, this template is uniformly used for the evaluation of 
validation studies. 
 
The current template is 
 
TEMPLATE_ESAC-WG_REPORT-v6.doc 
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ESAC Working Group 
 
Full title: ESAC Working Group on Eye Irritation Test Methods 
 
Abbreviated title:  ESAC WG Eye irritation 
 
 
The ESAC WG was established in March 2016 by written procedure to assist in the production of an 
ESAC Opinion  by undertaking a peer review of a three laboratory ring trial  of the  Ocular Irritection®  
(OI) Assay, a test method with a claimed wide applicability domain, developed for the prediction of 
the eye irritation potential of liquid and solid chemicals, specifically to distinguish chemicals requiring 
official classification for eye irritation or serious eye damage according to the United Nations Globally 
Harmonized System of Classification and Labelling of Chemicals (UN GHS. UN, 2015) from chemicals 
not requiring classification (no classification category; 'non-irritants').   
 
Following a teleconference on 6 May 2016 the ESAC WG met at EURL-ECVAM 11-13 May 2016 to 
conduct its peer review. 
 
 
The ESAC WG members appointed by ESAC were: 
 
 Dr. José M. Navas (ESAC Member, WG Chair) 
 Dr. Kristina Kejlová (ESAC Member) 
 Prof. Annette Kopp-Schneider (ESAC Member) 
 Dr. Renate Krätke (ESAC Member) 
 Dr. Jon Richmond (ESAC Member) 
 Dr. Dave Allen (Nomination by NICEATM/ICCVAM)  
 Prof. Kyung-Min Lim (Nomination by KoCVAM) 
 
 
ESAC Coordination:  
 Dr. João Barroso (ESAC Coordinator) 
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Abbreviations used in the document 
 BLR   Between-laboratory reproducibility 
 CI   Confidence Interval 
 EIT   Eye Irritation Test 
 ESAC   EURL ECVAM Scientific Advisory Committee 
 ESAC WG  ESAC Working Group 
 EU CLP   European Union Regulation on Classification, Labelling and Packaging  
of Substances and Mixtures 
 EURL ECVAM   European Union Reference Laboratory for Alternatives to  
   Animal Testing 
 GLP   Good Laboratory Practice  
 IATA   Integrated Approach to Testing and Assessment 
 IDE   Irritation Draize Equivalent 
 MAS   (in vivo, Draize test) Maximum Average Scores 
 MQS   Maximum Qualified Score (highest estimated IDE score) 
 OD   Optical density 
 OECD   Organisation for Economic Co-operation and Development  
 OI   Ocular Irritection® (OI) Assay 
 PM   Prediction Model 
 RhCE   Reconstructed Human Cornea-like Epithelium 
 ROC   Receiver Operation Characteristics 
 SOP   Standard Operating Procedure 
 TST   Test Submission Template 
 UN GHS  United Nations  Globally Harmonized System for the Classification    
and Labelling of Chemicals. 
 VMG   Validation Management Group 
 WLR   Within-laboratory reproducibility 
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1. Study objective and design 
1.1 Analysis of the clarity of the study objective's definition 
(a) ESAC WG summary of the study objective as outlined in the Test Submission 
The prospective Ocular Irritection® (OI) assay validation study pre-defined study objectives were: 
 To formally evaluate the usefulness in terms of relevance (predictive capacity) and reliability 
(transferability, and reproducibility within and between laboratories) of the OI assay to 
reliably discriminate chemicals not requiring classification for serious eye damage/eye 
irritancy (No Category) from chemicals requiring classification and labelling (Category 1 and 
Category 2) according to the UN GHS Classification and Labelling of Chemicals (UN GHS. UN, 
2015) and as implemented by the EU CLP regulation (EU CLP. EC, 2008a). This test method is 
not intended to differentiate between GHS Categories 1 (irreversible effects) and 2A-B 
(reversible effects). 
o N.B. The test method was not designed, intended, or evaluated to test gases 
or aerosols. 
 A further post-hoc evaluation was performed to evaluate the usefulness of the OI assay to 
discriminate chemicals inducing serious eye damage (UN GHS Category 1) from other classes. 
 In addition, to produce evidence and analysis to support the test method being incorporated 
into a tiered testing strategy (so-called Bottom-Up/Top-Down testing strategy, Scott L. et al., 
2010). The ultimate purpose of such a tiered testing strategy being to replace the traditional 
in vivo Draize eye test [Method B.5 of EC Regulation 440/2008 (EC, 2008b) or OECD TG 405 
(OECD, 2002)]. 
 
(b) Appraisal of clarity of study objective as outlined in the Test Submission 
The ESAC WG believes that the study objectives were sufficiently clear, and determined the way the 
study was designed, conducted, analysed, and reported in the TST. The WG notes that the original 
goal of the prospective validation study, as reflected for example in chemical selection, was  
restricted to discriminating eye irritants from non-classified (Bottom-Up approach) (Scott et al., 2010). 
The data and analysis submitted in the TST, however, also includes consideration of its use in a Top-
Down approach. 
 
1.2 Quality of the background provided concerning the purpose of the test method  
The TST clearly describes the intended application of the OI assay as being for regulatory testing.  
The TST discusses the possible use of this assay in future in vitro tiered testing strategies (Scott et al, 
2010) within an integrated approach using strategic combinations of alternative test methods to 
replace the Draize eye test. 
 
(a) Analysis of the scientific rationale provided in the Test Submission 
The TST describes the relevance and scientific rationale of the OI assay as evaluating the ocular 
hazard effects of chemicals based on the premise that eye irritation and corneal damage after 
exposure to irritating chemicals results from the disruptive effects ocular irritants may have on the 
highly organized structure of corneal macromolecular matrix of proteins and carbohydrates.  
According to Scott et al. (2010) mechanisms of eye irritation within the cornea include ‘coagulation’ 
(the precipitation/denaturation of macromolecules, particularly proteins), ‘saponification’ (the 
breakdown of lipids), and ‘actions of macromolecules’. The reported mechanisms leading to ocular 
irritation in vivo include denaturation of collagen, loss of glycosaminoglycans (polysaccharide), and 
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saponification of lipids such as in the case of alkalis; coagulation and precipitation of proteins such as 
in the case of acids; dissolution of lipids such as in the case of solvents (Eskes et al., 2010). 
The OI assay manufacturer considers the identity of the raw material used to produce the 
macromolecular assay matrix to be confidential: however the ESAC WG finds it is already identified in 
a number of public domain resources.  
The raw material for OI assay matrix is plant-based, and purchased in bulk in powder form from a 
third party: neither the supplier nor the assay manufacturer have chemically characterised, defined, 
or standardised the plant extract or the chemical composition of the assay matrix. The information 
available to the ESAC WG does not explain why or how the raw material was originally selected to 
produce the test kit macromolecular matrix as a surrogate for the human cornea.  
The supporting documentation claims a mechanistic basis based on the resemblance of the assay 
macromolecular matrix with the human cornea. However, in addition to the assay matrix never 
having been fully chemically characterised and not being of mammalian origin, there is no detailed 
description of the nature of the healthy human corneal matrix, or how it changes after exposure to 
ocular irritants. The documentation also does not explain how the physical chemical alterations 
occurring in the kit matrix upon exposure to irritant chemicals compare to effects observed with the 
in vivo Draize eye test. Furthermore, it is not clear to the ESAC WG why the chemical changes 
induced in the assay matrix should be specific to ocular irritants, rather than being also applicable to 
other classes of irritants (e.g. skin irritants). The ESAC WG therefore considers that the OI assay's 
mechanistic relevance to predict adverse ocular effects of chemicals in humans is poorly defined and 
that the data presented in the test submission represent an empirically observed relationship 
(correlative relationship), rather than a proven mechanistic relationship, between changes to the 
matrix and the potential of test chemicals to produce ocular irritation. 
The OI assay is not intended to provide insights into persistence of chemically-induced ocular injuries, 
which could result in the underprediction of chemicals classified in vivo as Category 1 due only to 
persistence of effects, if the test method is used to identify Category 1 chemicals, e.g., as a first step 
in a Top-Down approach. In addition, if this test method is to be used to identify non-irritants within 
an Integrated Approach to Testing and Assessment (IATA) then the ESAC believes other test methods 
may be needed to assess the vascular and inflammatory components of the adverse outcome 
pathway for eye irritation, and to take account of the lack of epithelial barrier function. 
 
(b) Analysis of the regulatory rationale provided in the Test Submission 
The TST identifies relevant regulatory requirements. In the view of the ESAC WG the relevant 
legislation and regulations are appropriately referenced; and the regulatory requirements and the 
role of the non-animal methods in the context of the regulatory requirements are adequately 
specified. 
If validated and accepted for regulatory use, the OI assay could contribute to a reduction in animal 
testing by reliably identifying chemicals not requiring classification (No Category) and chemicals 
inducing serious eye damage (Category 1) when used within an appropriate non-animal testing 
strategy (Scott et al, 2010). This ESAC WG considers that in view of the high prevalence of non-
classified chemicals (Adriaens et al, 2014), non-animal test methods validated for this purpose could 
contribute to reducing animal testing by identifying the much larger number of chemicals not 
requiring classification. 
 
1.3 Appraisal of the appropriateness of the study design 
The study and data reported in the TST generally comply with the principles and criteria set out in the 
OECD Guidance Document on the Validation and International Acceptance of New or Updated Test 
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Methods for Hazard Assessment (No. 34. OECD, 2005), and described in the generally accepted 
Modular Approach to validation (Hartung et al, 2004). 
The ESAC WG notes in particular: 
 the comprehensive SOP for test method implementation; 
 the chemical selection for the prospective study was structured in favour of assay use in a  
Bottom-Up approach; 
 appropriate training facilitating transfer to a naïve laboratory was planned and undertaken; 
 there was generally appropriate separation of responsibilities for the ring trial (project 
management, chemicals management, data management); 
 defined controls and calibration materials were used; 
 descriptions were provided of how WLR, BLR, specificity, sensitivity, accuracy were to be 
calculated; 
 the degree of independence used for data statistics analysis. 
However, the ESAC WG also notes the following shortcomings: 
 there is no quality assurance system to define and control the chemical composition of the 
raw material used to produce the assay matrix, and no detailed chemical specification or 
chemical characterisation of the assay matrix before test kit batch release;  
 there is a lack of transparency associated with the software and algorithms used in the test 
method;  
 information required for the users and potential users to interpret some test results is 
considered confidential;   
 the independent statistician involved in the study was also the vice-chair of the Validation 
Management Group (VMG); 
 in addition to qualified and non-qualified runs the submitter makes use of a third category, 
excluded runs, which impacts on the calculation of the test performance when comparisons 
are made with the reported performance of other test methods. 
For the prospective ring trial, reliance was placed on a statistical power analysis (sample size 
calculation) estimating the minimum requirements for the assay’s use within a Bottom-Up approach 
(n=50). To make provision for unforeseeable events, 56 chemicals were used in the ring trial (five of 
which were subsequently excluded from the analysis of the test method performance). 
The relevance and reliability of the OI assay as reported by the test manufacturer also took account 
of retrospective data from 45 chemicals, eight of which were also used in the prospective ring trial.  
Accordingly, the analysis presented by the test method developer in the TST is based on the 
classification of the eye damage/irritation potential of a total of 88 chemicals (n= 56 – 5 + 45 – 8 = 88).  
The test method performance acceptance criteria proposed by the test manufacturer are based on 
the reported performance of other validated in vitro methods used to assess chemical eye 
damage/irritation potential, not all of which would fulfil similar roles in a future integrated testing 
strategy. 
In its scientific review of the study, taking into account the study findings, and the OI assay TST 
conclusions, the ESAC WG concludes that, subject to specific qualifications set out above and below, 
the study design was generally appropriate and robust, the acceptance criteria applied to the test 
results were appropriate. In addition, the study report provides sufficient data, evidence and analysis 
for the ESAC WG to conduct a peer review of to what extent the study objectives were satisfied.  
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1.4 Appropriateness of the statistical evaluation 
Although the Study Plan specifies the production of a stand-alone statistical report, there is no formal 
separate statistical report included in the documents available to the ESAC WG. The available 
statistical information is contained in the TST and associated annexes and additional information 
supplied by the test manufacturer at the request of the ESAC WG.  
The initial calculation to determine the minimal number of chemicals to be used in the ring trial was 
appropriate for a test intended to be used within a Bottom-Up approach (see 1.3 above). 
In the case of the WLR and BLR the WG considers that although point estimates were calculated, 
Confidence Intervals (CIs) were not supplied, therefore the precision of the estimated WLR and BLR 
values cannot be fully assessed. The ESAC WG also believes that including “concordant” non-qualified 
and excluded test results in the analysis is not sound. 
The predictive capacity appears to have been calculated correctly, and one-sided 95 %-CIs (similar to 
two-sided 90 %-CIs) based on resampling methods were supplied. However, the WG notes that 
validation studies for other test methods typically provide two-sided 95 %-CIs. Furthermore, there is 
a lack of clarity about how the resampling was performed. 
The ESAC WG cannot say with certainty whether the cumulative effects of these perceived short-
comings, including the provision made to “exclude” test runs, may have tended to over-estimate the 
performance of the assay in comparison to the datasets presented for evaluation from other 
validation studies. 
 
 
2. Collection of existing data 
2.1 Existing data used as reference data 
The TST and annexes provide sufficient information on this point. The TST references and relies on an 
extensive collection of information generated before and during the development and pre-validation 
of the test method. 
Chemical selection was carried out in collaboration with EURL ECVAM in order to avoid bias in the 
process, to safeguard the independence of the chemicals selection process, and to facilitate 
comparison of OI assay’s performance to other assays evaluated or being evaluated for eye 
damage/irritation testing.  
Databases consulted as sources for chemical selection included the ICCVAM (TSCA) list of reference 
chemicals (ICCVAM, 2007), the ECETOC database (ECETOC, 1998) and EURL ECVAM suggested 
chemicals. 
The essential requirements for chemical selection for the ring trial were toxicological and physico-
chemical properties, chemical class, as well as the availability of complete and quality assured 
supporting in vivo data to allow comparative evaluation of the predictive capacity of the test method 
as measured against the in vivo (Draize eye test) reference method. 
According to the performed calculations, the minimum number of chemicals needed from a 
statistical point of view for the evaluation of the predictive capacity of the assay for use within a 
Bottom-Up approach was 50 (27 non-classified + 23 classified chemicals). Additionally, six more 
chemicals were included (4 non-classified and 2 classified ones) to compensate for unforeseeable 
events. In conclusion, a total of 56 chemicals were selected for the prospective ring trial, including 31 
non-classified and 25 classified chemicals for eye damage/irritation (12 Category 1 and 13 Category 2 
chemicals).  
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A wide range of chemical properties, use/function (surfactants were also included), and physico-
chemical properties were taken into consideration for the selection. In addition, the US EPA  eye 
hazard categories were also described (18 EPA Category IV, 20 EPA Category III, 6 EPA Category II, 7 
EPA Category I and 5 having study criteria not met to be able to assign an unequivocal EPA Category).  
The only other consideration was to ensure that the selected chemicals were consistent with the pre-
defined applicability domain of the OI assay as defined in its SOP. 
 
2.2 Existing data used as testing data 
The TST analysis also took account of test results with additional 45 chemicals. Such results were 
generated with the same protocol as that used in the prospective validation study. All chemicals had 
good quality in vivo data and fell within the pre-defined OI assay applicability domain. 37 chemicals 
were not tested in the prospective validation dataset, but eight had also been tested during the 
prospective validation study.  
As a consequence, and disregarding the four chemicals whose ring trial results were classified as 
“excluded” in all tests performed by the three laboratories and one other chemical for which "non-
qualified" results were obtained in all tests performed by two of the three laboratories (with the 
third laboratory obtaining three qualified tests), a total of 88 single chemicals with both in vivo and in 
vitro data were used by the test manufacturer to evaluate the predictive capacity of the OI assay (n= 
56 – 5 + 45 – 8 = 88. See 1.3 above).  
These chemicals comprised 43 UN GHS / EU CLP Non-Classified and 45 UN GHS / EU CLP Classified 
including 20 Category 1 and 25 Category 2 chemicals (21 Cat. 2A and 4 Cat. 2B). The composite 
dataset had a majority of liquids as compared to solids (56 liquids, 25 solids, and 7 viscous materials). 
Furthermore, the distribution according to the US EPA classification categories included 26 EPA Cat IV, 
26 EPA Cat III, 15 EPA Cat II, 13 EPA Cat I and 8 to which no unequivocal EPA Category could assigned. 
 
2.3 Search strategy for retrieving existing data 
See Section 2.1 above. 
 
2.4 Selection criteria applied to existing data 
See Sections 2.1 and 2.2 above. 
 
 
3. Quality aspects relating to data generated during the study 
3.1 Quality assurance systems used when generating the data 
The TST claims laboratories participating in the prospective ring trial worked in accordance with 
OECD GLP principles, such as, but not limited to, the use of SOPs, adequate data recording, and 
record keeping. No further information was supplied. 
 
3.2 Quality check of the generated data prior to analysis 
The data management procedures and statistical tools and methods applied were approved by the 
Ocular Irritection® test method VMG. The independent statistician who analysed the data was also 
vice-chairman of the VMG. 
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According to the project plan, raw data produced by the participating laboratories were entered into 
spreadsheets provided by the lead laboratory. The study biostatistician collated, audited and 
analysed the data. The data compiled were also audited by the participating laboratories. However, 
there is no formal separate statistical report included in the documents available to the ESAC WG. 
4. Quality of data used for the purpose of the study (existing and
newly generated) 
4.1 Overall quality of the evaluated testing data (newly generated or existing) 
The data were of sufficient quality to apply the predetermined acceptance criteria and prediction 
model.  
However, the ESAC WG felt it necessary to conduct supplementary analysis in view of the perceived 
shortcomings in the manufacturer's data analysis. See 1.4 above. 
4.2 Quality of the reference data for evaluating relevance1 
Draize eye test reference data, as those used in the present study, are considered those of the best 
quality for the purpose of the validation exercise. The quality of the reference data used here is 
equivalent to that of data used in previous in vitro test method eye damage/irritation validation 
studies. 
4.3 Sufficiency of the evaluated data in view of the study objective 
The sample size exceeded the minimum number of chemicals as determined by the power 
calculation for Bottom-Up analysis. See sections 1.2 and 2.2 above. 
The assumptions made for the sample size calculation (with an assumed sensitivity of 95 % with 
lower confidence bound of 75 %, and a specificity of 50 % with lower confidence bound of 25 %) 
were close to the values obtained in the final evaluation of the predictive capacity (sensitivity was 
slightly lower and specificity slightly higher than expected; see 10.1 below). In the prospective 
validation study 9 % of tests (46 out 504) were coded as excluded or non-qualified (representing, out 
of 56 chemicals, 4 with excluded results in 9 out of 9 tests, 1 with exclude in results in 4 out of 9 tests 
and 1 with "non-qualified" results in 6 out of 9 tests). The 5 chemicals with a majority of excluded of 
non-qualified results were then excluded from predictive capacity analyses due to issues 
encountered with the blank check (blank max failed or blank not flat).  See sections 1.3, 1.4, and 2.2 
above. 
1
 OECD guidance document No. 34 on validation defines relevance as follows: "Description of relationship of the 
test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to 
which the test correctly measures or predicts the biological effect of interest. Relevance incorporates 
consideration of accuracy (concordance) of a test method." 
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5. Test definition (Module 1) 
5.1 Quality and completeness of the overall test definition  
The Ocular Irritection® assay is based on the Eytex® method (Kelly, 1989; Gordon, 1992) taking 
account of recommendations made by Balls et al. (1995). It comprises single protocol, clear 
procedures for surfactant testing, and a defined applicability domain. 
The major underlying assumption behind the Ocular Irritection® assay is that eye irritation and 
corneal injury after exposure to irritant chemicals result from the disruptive effects those chemicals 
have on the highly organized matrix structure of corneal proteins and carbohydrates. The test 
method utilises a plant based matrix (derived from jack bean Canavalis enisformis. Loprieno, 1995; 
see: link 1; link2), which is claimed to become turbid after exposure to ocular irritants. 
The chemical composition of the Ocular Irritection® assay matrix is not fully characterized or 
specified in the test submission. Supplementary information supplied by SeCAM (SeCAM Services & 
Consultation on Alternative Methods Sagl, Switzerland) indicates neither the chemical composition of 
the raw material or the resulting test matrix have been fully chemically characterised or defined 
either by the supplier or test kit manufacturer. 
To perform the assay, test materials are applied to the surface of the Ocular Irritection® assay plant-
extract matrix, with a membrane disk used to ensure proper coverage, in defined quantities and for a 
set time. Chemicals that produce ocular irritation are expected to produce physico-chemical changes 
including alterations in protein conformation and the degree of hydration resulting in turbidity in the 
matrix, with the turbidity degree being proportionate to the ocular irritation potential of the test 
material – as judged against positive and negative controls, and calibration materials. The change in 
matrix turbidity produced by five concentrations of the test material (and the control and calibration 
samples) is measured by the light scattering detected by a spectrophotometer set to a wavelength of 
405 nm. The software supplied with the assay then calculates a dose response curve for the test 
material (the precise algorithms used are not described in detail in the TST). The turbidity as 
estimated by the software is converted to a numerical Irritection Draize Equivalent (IDE), and the 
highest estimated IDE score, termed the Maximum Qualified Score (MQS), is then used in  the 
prediction model to categorise the ocular hazard potential of the test chemicals according to the UN 
GHS and EU CLP classification systems (UN, 2015; EC, 2008a). 
The Ocular Irritection® assay software automatically performs a number of qualification checks 
against pre-defined parameters to ensure assay performance. The software has been designed to 
accept the sample data only if specific acceptance criteria as detailed in the TST are met. Results may 
be shown as qualifying, non-qualifying, or excluded. Users are provided with instructions to deal with 
ambiguous or equivocal results. 
The Prediction Model (PM) is based on that initially developed for the Eytex assay to predict in vivo 
Maximum Average Scores (MAS). The PM as used for this validation study was confirmed as optimal 
with the Ocular Irritection® assay for application to UN GHS/EU CLP classification using a set of 23 
chemicals (9 non-classified, 12 Category 2 and 2 Category 1 chemicals based on the UN GHS/EU CLP 
classification system) (Eskes et al., 2014). In the prospective validation study the PM was used 
primarily to distinguish classified from non-classified chemicals using the previously existing cut-off of 
12.5 (i.e. Bottom-Up approach) (Table 5.1.1). 
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Table 5.1.1. Maximal Qualified Score (MQS) values and correspondence with the degree of ocular 
irritancy and the UN GHS/EU CLP classification. 
 
 
 
 
 
 
 
After the ring trial a post-hoc evaluation of the data was carried out to evaluate the predictive 
capacity of the assay using a cut-off value of 30.0 for the identification of UN GHS/EU CLP Category 1 
(i.e. Top-Down approach) (Table 5.1.2). 
 
Table 5.1.2. Maximal Qualified Score (MQS) values and correspondence with the degree of ocular 
irritancy and the UN GHS/EU CLP classification. 
 
 
 
 
 
 
 
From the information available it is not clear why the changes to the test method matrix should be 
specific or restricted to ocular irritants, as opposed to other categories of irritants. Nevertheless the 
empirical evidence tends to confirm a correlative relationship with the in vivo results rather than a 
proven biological/mechanistic relationship as claimed by the submitter. 
 
5.2 Quality and completeness of the documentation concerning SOPs and prediction 
models 
The SOPs are detailed and complete and the PM is defined (see section 5.1). However, for the 
evaluation of ambiguous and equivocal results those using the assay must refer to a supplementary, 
confidential facts sheet provided by the manufacturer. 
 
 
6. Test materials 
6.1 Sufficiency of the number of evaluated test items in view of the study objective 
See sections 1.3, 2.1, and 2.2 above. 
 
6.2 Representativeness of the test items with respect to applicability 
See sections 2.1 and 2.2 above. 
 
 
Maximal Qualified Score 
(MQS) 
UN GHS / EU CLP 
classification 
0 – 12.5 No Category 
> 12.5  Categories 1 and 2 
Maximal Qualified Score 
(MQS) 
UN GHS / EU CLP 
classification 
0 – 30 No Category and Category 2 
> 30  Category 1 
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7. Within-laboratory reproducibility (WLR) (Module 2) 
7.1 Assessment of repeatability and reproducibility in the same laboratory 
The within-laboratory reproducibility was assessed in two ways as the software provides Maximum 
Qualified Score, which ranges from 0 to 51 being truncated at the upper border of 51, and 
simultaneously also indicates if a sample is not qualified (NQ) or excluded. The rules for assessing 
such cases are defined in the Ocular Irritection SOP. 
Firstly, the analyses focused on the chemicals with non-truncated Maximal Qualified Scores for which 
the SD were calculated. The standard deviation of the three samples per chemical was considered as 
an appropriate measurement of within-laboratory reproducibility. Considering conservatively an SD 
below 4, which according to the submitter represents a low variability in relation to the dynamic 
response range of the OI assay that spans from 0 to 51, as an indicator for acceptable within-
laboratory reproducibility, the calculation resulted in 93.3 % (IVI), 84.4 % (IIVS) and 91.3 % (RP) WLR. 
These values are reported in the TST as a point estimate rather than with CIs. Although the ESAC WG 
has not calculated the CIs, based on the data sets they should have been acceptably narrow. 
Secondly, the WLR was evaluated individually for each laboratory and for both cut-offs (i.e., 12.5 for 
Bottom-Up and 30.0 for Top-Down) in terms of concordance of the predictions of the three 
independent experiments carried out per chemical in each laboratory. In this case, the WLR values 
were calculated using data from qualified tests, but also with chemicals that all three laboratories 
consistently coded as non-qualified or excluded being deemed to be concordant and therefore 
included in the calculation. The concordances based on predictions are shown in Table 7.1.1. The 
ESAC WG discovered two errors in the TST in the reporting of the WLR for RP: a total of 9 and not 8 
discordant predictions and a total of 47 and not 46 concordant predictions were obtained. The 
reported WLR value of 83.9 % for RP is nevertheless correct. 
 
Table 7.1.1. Calculation of WLR when considering consistent occurrence of "non-qualified" and 
"excluded" runs as concordant in the reproducibility evaluation of the OI assay. IVI, InVitro 
International laboratory; IIVS, Institute for In Vitro Sciences laboratory; RP, Res Pharma laboratory. 
 
 Within-laboratory Reproducibility 
 
Cut-off 12.5 Cut-off 30.0 
 IVI IIVS RP IVI IIVS RP 
concordant predictions 45 42 41 46 43 43 
discordant predictions 6 8 11 5 7 9 
concordant excluded 4 5 4 4 5 4 
concordant NQ 1 1 0 1 1 0 
overall concordant 50 48 45 51 49 47 
% concordance 89.3 % 85.7 % 80.4 % 91.1 % 87.5 % 83.9 % 
 
However, the ESAC WG believes that including “concordant” non-qualified and excluded test results 
in the analysis is not sound. Taking this into account, the WLR values and their respective Wilson 
two-sided 95 %-CIs were recalculated by the ESAC WG including only qualified results. The ESAC WG 
places reliance on the WLR values calculated on this basis (Table 7.1.2.). 
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Table 7.1.2. Calculation of WLR and BLR NOT considering consistent occurrence of "non-qualified" 
and "excluded" runs as concordant in the reproducibility evaluation of the OI assay. The values in 
brackets correspond to Wilson two-side 95 %-CIs. IVI, InVitro International laboratory; IIVS, Institute 
for In Vitro Sciences laboratory; RP, Res Pharma. 
 
 
Within-laboratory Reproducibility 
 
Cut-off 12.5 Cut-off 30.0 
 
IVI IIVS RP IVI IIVS RP 
concordant predictions 45 42 41 46 43 43 
discordant predictions 6 8 10 5 7 8 
% concordance 
88.2 % 
(76.6-94.5 %) 
84.0 % 
(71.5-91.7 %) 
80.4 % 
(67.5-89.0 %) 
90.2 % 
(79.0-95.7 %) 
86.0 % 
(73.8-93.1 %) 
84.3 % 
(72.0-91.8 %) 
 
7.2 Conclusion on within-laboratory reproducibility as assessed by the study 
See 7.1 
The OI WLR appears to be similar or lower than what was observed in the other available in vitro 
methods for serious eye damage/eye irritation testing, especially the RhCE-based test methods. A 
higher variability was obtained than what could be expected from a purely chemically defined test 
method.  
 
 
8. Transferability (Module 3) 
8.1 Quality of design and analysis of the transfer phase 
This was generally well planned and conducted.  
InVitro International, the test manufacturer, has well established training procedures, which last 2 
days and encompass the conduct of the Ocular Irritection® assay; an explanation of the Ocular 
Irritection® assay software; and the evaluation, review and discussion of results and troubleshooting. 
This training was provided by IVI to IIVS and ResPharma before the prospective chemical testing was 
undertaken. 
For the transferability study, four chemicals with different physical properties (two liquids, one solid 
and one surfactant) having different in vivo classifications (two UN GHS / EU CLP Category 2, and two 
Non-classified chemicals) were used, being tested three separate times using three different Ocular 
Irritection® kits by the operators.  
The transferability of the updated Ocular Irritection® protocol was therefore evaluated in the three 
laboratories: the first, InVitro International (IVI, California, US) had over 20 years of experience with 
this class of assay; the second, ResPharma (RP, Italy) also had experience with this class of assay; and 
the third, the Institute for In vitro Sciences (IIVS, Maryland, US) has considerable experience with in 
vitro test systems, but no previous experience with this class of assay. The fact that the three 
laboratories were based on two different continents also allowed information to be gathered on 
issues that may arise from distribution of the test kits. 
The inter-laboratory concordance of classifications obtained during the transferability study was 
100 %, the within-laboratory variability was low (SD ≤ 1.7) and the variability between laboratories 
within an acceptable range (SD ≤ 3.6).  
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8.2 Conclusion on transferability to a naïve laboratory / naïve laboratories as assessed by 
the study 
According to the information provided the OI assay seems to be easily transferable to another 
laboratory with only general working expertise required for the lab personnel. 
However, the ESAC WG noted that the participating laboratories were allowed to freely 
communicate and meet during the training and transfer phases of the study. Moreover, three of the 
four chemicals used in training were also used in the transfer study and three of the chemicals used 
in the training and transfer phase were subsequently included in the prospective validation study. 
The ESAC WG believes that it would have been preferable to use completely new chemicals instead.  
 
 
9. Between-laboratory reproducibility (BLR) (Module 4) 
9.1 Assessment of reproducibility in different laboratories 
As with the WLR, the BLR was evaluated in two ways. 
First, when MQSs were available for experiments conducted at all three laboratories with a test 
chemical (n=45), a mean MQS for the chemical was calculated for each laboratory, with the SD of the 
three laboratory means being considered as an indicator of BLR. For 38 of the 45 chemicals the SD 
was < 4. The overall mean (SD: 2.5, CV: 17 %) and median (SD: 2.1; CV: 14 %) obtained between-
laboratories was also reported. 
In addition, the BLR was evaluated for both cut-offs (i.e., 12.5 for Bottom-Up and 30.0 for Top-Down) 
in terms of the percentage of concordant predictions among the three laboratories based on the 
majority laboratory classification. The calculation was performed on the dataset of 56 chemicals 
tested (31 non-classified, 25 classified as UN GHS/EU CLP Cat 1 (12) or Cat 2 (13). Thirty two were 
liquids and 24 solids. Again, for the analysis in the TST non-qualified and excluded test results were 
included in this analysis. Using this approach, 42 (cut-off 12.5) and 43 (cut-off 30.0) of the 56 test 
chemicals were concordantly classified in all laboratories. Four chemicals were concordantly 
“excluded” in all laboratories, resulting in a between-laboratory reproducibility of 82.1 % (46/56) for 
the Bottom-Up approach (cut-off 12.5) and of 83.9 % (47/56) for the Top-Down approach (cut-off 
30.0). Results are shown in Table 9.1.1. 
 
Table 9.1.1. Calculation of BLR when considering consistent occurrence of "non-qualified" and 
"excluded" runs as concordant in the reproducibility evaluation of the OI assay. 
 
Between-laboratory Reproducibility 
 
Cut-off 12.5 Cut-off 30.0 
concordant predictions 42 43 
discordant predictions 10 9 
concordant excluded 4 4 
concordant NQ 0 0 
overall concordant 46 47 
% concordance 82.1 % 83.9 % 
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As in the case of the WLR, the ESAC WG believes that including “concordant” non-qualified and 
excluded test results in the analysis is not sound. Taking this into account, the BLR values and their 
respective Wilson two-sided 95 %-CIs were recalculated by the ESAC WG including only qualified 
results. According to this approach,, the resulting BLR concordance would be of 84.0 % (42/50) for 
the Bottom-Up approach, and of 86.0 % (43/50) for the Top-Down approach (Table 9.1.2). See 
section 9.2. 
 
Table 9.1.2. Calculation of BLR NOT considering consistent occurrence of "non-qualified" and 
"excluded" runs as concordant in the reproducibility evaluation of the OI assay. The values in 
brackets correspond to Wilson two-side 95 %-CIs. 
 
Between-laboratory Reproducibility 
 
Cut-off 12.5 Cut-off 30.0 
concordant predictions 42 43 
discordant predictions 8 7 
% concordance 
84.0 % 
(71.5-91.7 %) 
86.0 % 
(73.8-93.1 %) 
 
In addition the ESAC WG notes that three of the chemicals used to the BLR calculation where also 
used for the training, transfer and proficiency testing. 
 
9.2 Conclusion on between-laboratory reproducibility as assessed by the study 
The ESAC WG believes that the reproducibility of the Ocular Irritection® assay is best evaluated using 
the BLR values not including concordant “non-qualified” and “excluded” results and including only 
“qualified” results. On the basis of the prospective validation data, using a total of 50 chemicals 
qualified for BLR, the corrected values would be 84 % (42/50) and 86 % (43/50) for the Bottom-Up 
and the Top-Down approaches, respectively. 
This slightly improves the BLR for both the Top-Down (from 83.9 % to 86 %) and the Bottom-Up 
(82.1 % to 84 %) approaches. 
The WG recognised that three chemicals used in the training and transfer phase were also used to 
calculate the reproducibility of the test method (BLR).  
The ESAC WG noted that the WLR values for the laboratories IIVS (Bottom-Up: 84 % (42/50), Top-
Down: 86 % (43/50)) and RP (Bottom-Up: 80.4 % (41/51), Top-Down: 84.3 % (43/51)) (Table 7.1.2 
above) are equal or lower than the BLR value, and that the BLR is similar or lower than which is 
observed in the other available in vitro methods for serious eye damage/eye irritation testing, 
especially the RhCE-based test methods. Although acceptable, a lower variability would have been 
expected for this assay as compared to other biological assays constituted of living cells or tissues. 
 
 
ESAC WORKING GROUP REPORT  Page | 47 
10. Predictive capacity and overall relevance (Module 5)  
10.1 Adequacy of the assessment of the predictive capacity in view of the purpose 
Altogether, data from a total of 88(+1) single chemicals having parallel in vivo and in vitro data were 
used to evaluate the predictive capacity of the Ocular Irritection®, including 51(+1) chemicals from 
the prospective validation study and 37 additional chemicals having existing in vitro data generated 
with the same OI SOP. 
Due to the unbalanced number of repetitions between the prospective and the retrospective 
datasets available, the majority of predictions available for each chemical (mode) was preferred by 
the VMG as the means of expressing the predictive capacity of the assay. The concordance of these 
predictions with the expected result as defined by the in vivo-based classifications (segregated into 
UN GHS / EU CLP classified vs. non-classified chemicals, and UN GHS / EU CLP Category 1 vs. non-
Category 1 chemicals) were assessed by means of 2x2 contingency tables, and then the specificity, 
sensitivity and overall accuracy were calculated. 
For specificity and sensitivity one-sided 95 %-CIs were calculated using the mid-p approach (Agresti 
and Gottard, 2005) with the R package ‘PropCIs’. This analysis was complemented by a) deriving 
point estimates of specificity, sensitivity and concordance using an often called ‘weighted’ approach 
that considered for each chemical the proportion of correct classification of repeat experiments, and 
by b) a resampling approach providing probability distributions for specificity and sensitivity, from 
which the 5 % and 95 %-quantiles were used to describe the expected range of the two parameters 
(i.e., similar to two-sided 90 %-CIs). Finally, receiver operation characteristics (ROC) curves were 
produced to more fully characterize the predictive capacity of the Ocular Irritection® assay, and to 
assess the appropriateness of the MQS cut-offs i) 12.5 to identify GHS non-classified chemicals in a 
Bottom-Up approach, and ii) 30.0 to identify GHS Category 1 chemicals in a Top-Down approach. 
The ESAC is of the opinion that the calculations of Predictive Capacity should reflect in the best way 
possible the real-life testing situation. Since with the OI assay one single test result will be used to 
derive one final prediction, the ESAC considers that the majority of predictions is sub-optimal to 
express the Predictive Capacity of the test method. In ESAC's opinion, more truthful point estimates 
can be obtained by using the weighted calculation or by resampling of the multiple data generated in 
the validation study. Both the weighted calculations (with two-sided 90 %-CIs obtained from 
resampling) and predictive capacity values obtained from the majority of predictions (with Wilson 
two-sided 95 %-CIs calculated by the ESAC WG) are given in Tables 10.1.1, 10.1.2 and 10.1.3 below 
for comparison. Published predictive capacity values for other serious eye/damage eye irritation in 
vitro methods are also provided for comparison in Tables 10.1.1 and 10.1.2. 
Out of the 56 chemicals tested in the ring study, five chemicals were not included in the analyses of 
predictive capacity performed due to the fact that they were either excluded (4 chemicals) or not-
qualified (1 chemical) by the Ocular Irritection® software in the majority of the available 
tests/experiments (6 or 9 out of 9). These represent one Cat. 1 chemical, two Cat. 2 chemicals and 
two Non-Classified chemicals. As a consequence, out of the 56 tested chemicals a total of 51 
chemicals were considered in the analyses of the predictive capacity of the OI assay. These represent 
20 solids, 27 liquids and 4 viscous chemicals; 29 UN GHS No Category, 11 Category 1 and 11 Category 
2 chemicals. 
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Predictive capacity for the identification of UN GHS / EU CLP Non-classified chemicals 
When used for the identification of UN GHS non-classified versus classified materials (based on the 
existing cut-off of 12.5) the OI assay showed an overall sensitivity of 90.7 % (with two-sided 90 %-CIs: 
87.0 % and 93.5 %), a specificity of 58.9 % (with two-sided 90 %-CIs: 53.5 % and 65.1 %) and an 
overall accuracy of 75.3 %, based on weighted calculations (Table 10.1.1). Some organic functional 
groups were found possibly to correlate with the observed mispredictions. In particular, acrylate, 
carboxamide, and cycloalkenes. If, despite their small number, chemicals containing these functional 
groups were excluded from analyses, the obtained dataset resulted in a sufficiently large dataset 
(n=79) to still derive sound conclusions. Such findings are comparable to the currently accepted 
OECD test methods as shown in Table 10.1.1.  
 
Table 10.1.1. Predictive capacity of the OI for the identification of UN GHS/EU CLP non-classified 
chemicals and comparison to published values for other in vitro methods. 
  
 
OI 
n=88 
weighted 
(resampling 
90 %-CI) 
OI* 
n=79 
weighted 
(resampling 
90 %-CI) 
OI 
n=88 
majority of 
predictions 
(Wilson 
95 %-CI) 
OI* 
n=79 
majority of 
predictions 
(Wilson 
95 %-CI) 
BCOP  
(TG437) 
n=196 
majority of 
predictions 
ICE  
(TG 438) 
n=152 
majority of 
predictions 
STE** 
 (TG 491) 
n=101 
EpiOcular 
EIT  
(TG 492) 
n=112 
weighted 
CM*** 
 (Draft TG) 
n=45 
weighted 
Accuracy 
75.3 % 
na 
80.5 % 
na 
76.1 %  
(67/88) 
(66.3-83.8 %) 
81.0 %  
(64/79) 
(71.0-88.1 %) 
68.9 %  
(135/196) 
82.2 %  
(125/152) 
90.1 %  
(91/101) 
80 %  
(n=112) 
68 %  
(n=45) 
Sensitivity 
90.7 % 
(87.0-93.5 %) 
96.4 % 
(92.9-100 %) 
93.3 %  
(42/45) 
(82.1-97.7 %) 
97.6 %  
(40/41) 
(87.4-99.6 %) 
100.0 %  
(107/107) 
98.6 %  
(72/73) 
98.1 %  
(53/54) 
96 %  
(n=57) 
100 %  
(n=22) 
Specificity 
58.9% 
(53.5-65.1 %) 
62.8 % 
(55.3-71.1%) 
58.1 %  
(25/43) 
(43.3-71.6 %) 
63.2 %  
(24/38) 
(47.3-76.6 %) 
31.5 %  
(28/89) 
67.1 %  
(53/79) 
80.9 % 
(38/47) 
63 %  
(n=55) 
32 %  
(n=23) 
* excludes chemicals containing the acrylate, carboxamide and cycloalkenes organic functional groups; 
** Only water-soluble chemicals or chemicals forming a uniform suspension, and excluding highly volatile 
substances and solid substances other than surfactants; 
 *** Only water-soluble surfactants and surfactant-containing formulations. 
 
Predictive capacity for the identification of UN GHS / EU CLP Category 1 chemicals 
For the identification of the UN GHS /EU CLP Category 1 chemicals a post-hoc evaluation of the entire 
dataset comprising both, the prospective validation dataset and the additional existing data from 
retrospective studies was carried out. When used for the identification of UN GHS Category 1 versus 
non-Category 1 chemicals (based on the cut-off of 30.0) the OI assay showed an overall specificity of 
80.9 % (with two-sided 90 %-CIs: 76.8 % and 84.1 %), a sensitivity of 53.3 % (with two-sided 90 %-CIs: 
50.0 % and 60.0 %), and an accuracy of 74.7 %, based on weighted calculations (Table 10.1.2). These 
values are compared with those of the currently accepted OECD in vitro test methods for eye hazard 
assessment in Table 10.1.2 below. 
Further investigations conducted by the VMG to better understand possible reasons for 
misclassification suggested that chemicals having the presence of the organic functional groups 
carboxylic acid and sulphate seemed to risk possible underpredictions of Cat. 1 chemicals as non-Cat. 
1 chemicals. Excluding chemicals having these functional groups from analyses resulted still in a 
sufficiently large dataset to make sound conclusions (n=74). In this case, a specificity of 80.0 % 
(48/60), a sensitivity of 71.4 % (10/14) and a concordance of 78.4 % (58/74) were obtained, based on 
the majority of predictions.  
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Table 10.1.2. Predictive capacity of the OI for the identification of UN GHS / EU CLP Category 1 
chemicals and comparison to published values for other in vitro methods. 
  
OI 
n=88 
weighted 
(resampling 90 %-CI) 
OI 
n=88 
majority of 
predictions 
(Wilson 95 %-CI) 
BCOP 
(TG 437) 
n=191 
majority of 
predictions  
ICE 
(TG 438) 
n=140 
majority of 
predictions  
FL 
(TG 460)  
n=151 
weighted 
STE 
(TG 491) 
n=120* 
CM 
(Draft TG) 
n=68* 
weighted 
Accuracy 
74.7 % 
na 
73.9 %  
(65/88) 
(63.8-81.9 %) 
78.5 %  
(150/191) 
85.7 %  
(120/140) 
77.5 %  
(117/151) 
85.0 %  
(102/120) 
88 %  
(n=68) 
Specificity 
80.9 % 
(76.8-84.1 %) 
80.9 %  
(55/68) 
(70.0-88.5 %) 
74.6 %  
(94/126) 
93.8 %  
(106/113) 
93.2 %  
(96/103) 
98.8 %  
(83/84) 
98 %  
(n=42) 
Sensitivity 
53.3 % 
(50.0-60.0 %) 
50.0 %  
(10/20) 
(29.9-70.1 %) 
86.2 %  
(56/65) 
51.9 %  
(14/27) 
43.8 % 
 (21/48) 
52.8 %  
(19/36) 
73 %  
(n=26) 
* water-soluble chemicals or chemicals forming a uniform suspension. 
 
Full predictive capacity point estimates as recalculated by EURL ECVAM on the basis of a weighted 
calculation are summarised in Table 10.1.3. 
 
Table 10.1.3. Evaluation of the OI assay predictive capacity for both Top-Down and Bottom-Up 
approaches. For each approach weighted calculations are provided. 
Predictive Capacity 
TOP-DOWN BOTTOM-UP 
Prospective 
data 
Combined 
prospective and 
retrospective data 
Prospective 
data 
Combined 
prospective and 
retrospective data 
Sensitivity 
42.4 % 
(4.67/11) 
53.4 % 
(10.67/20) 
87.4 % 
(20.11/23) 
90.7 % 
(41.71/46) 
False Negatives 
57.6 % 
(6.33/11) 
46.7 % 
(9.33/20) 
12.6 % 
(2.89/23) 
9.3 % 
(4.29/46) 
Specificity 
80.2 % 
(32.89/41) 
81.0 % 
(55.89/69) 
55.6 % 
(16.11/29) 
59.8 % 
(25.71/43) 
False Positives 
19.8 % 
(8.11/41) 
19.0 % 
(13.11/69) 
44.4 % 
(12.89/29) 
40.2 % 
(17.29/43) 
Overall Accuracy 
72.2 % 
(37.56/52) 
74.8 % 
(66.56/89) 
69.7 % 
(36.22/52) 
75.8 % 
(67.42/89) 
Total Mispredictions 
27.8 % 
(14.44/52) 
25.2 % 
(22.44/89) 
30.3 % 
(15.78/52) 
24.2 % 
(21.58/89) 
 
10.2 Overall relevance (biological relevance and accuracy) of the test method in view of 
the purpose 
In the view of the ESAC WG, the Ocular Irritection® assay shows rather low sensitivity and only 
moderate specificity for use within a Top-Down Approach. Much like other validated in vitro methods 
for identification of Category 1, the OI assay does not address persistence of chemically-induced 
ocular injuries and consequently is not able to correctly predict chemicals classified in vivo as 
Category 1 due only to persistence of effects. Therefore, the use of the OI test method as a first step 
in a Top-Down approach could result in the underprediction of this type of chemicals, which in part 
explains the poor sensitivity obtained in the validation study. 
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In addition, if this test method is to be used to identify non-irritants within an Integrated Approach to 
Testing and Assessment (IATA) then the ESAC believes other test methods may be needed to assess 
the vascular and inflammatory components of the adverse outcome pathway for eye irritation, and 
to take account of the lack of epithelial barrier function. 
Three chemicals used in the training and transfer phase were also used to calculate the predictive 
capacity. 
 
 
11. Applicability domain (Module 6)  
11.1 Appropriateness of study design to conclude on applicability domain, limitations and 
exclusions 
The manufacturer’s original claim was that the Ocular Irritection® assay is applicable to substances 
and mixtures, based on over 20 years of experience of testing cosmetics, consumer products, their 
ingredients and pharmaceuticals 
As a result of this long-standing experience, the manufacturer believes that the Ocular Irritection® 
assay has a well-established and defined applicability domain. It is not applicable to very acidic (pH < 
4.0) and very alkaline (pH > 9.0) materials, oils and water-insoluble organic chemicals; and non-ionic 
surfactants can cause assay interference. The test method also has limitation for the testing of 
intensely coloured materials generating high OD readings for blanks and samples. In addition volatile 
ketones have been found to result in under-estimation of irritancy due probably to evaporation. 
Finally, a number of false negatives (Urea at concentrations > 5 %) and false positives (Sorbitol at 
concentrations > 5 %, Manganese violet, Aluminum chlorohydrate, Aluminum zirconium 
chlorohydrate, Aluminum chloride, Titanium oxide, Zinc oxide, Silver salts, Ferrous sulfate, Zinc 
sulfate) have been identified. 
These materials were not tested within the validation study. 
In addition to the pre-established applicability domain described above, the validation study showed 
that for the identification of UN GHS / EU CLP non-classified chemicals, despite the small number, 
chemicals containing the acrylate, carboxamide or cycloalkene organic functional groups seemed to 
correlate with mispredictions, where acrylate seemed to correlate with possible under-predictions (1 
out of 1, and reported to possibly polymerize under light), cycloalkene with over-predictions (4 out of 
5), and carboxamide with both under- and over-prediction (1/2 and 3/3 respectively). 
Overall the developer provides a weak rationale for the assay limitations with respect to the 
applicability of the Ocular Irritection® assay to particular types of chemicals. In some cases the 
exclusion of chemicals is based on their experience with single or a very limited number of 
representative chemicals. The WG is not able to decide whether the number of chemicals is large and 
comprehensive enough to generalize their conclusions. 
 
11.2 Quality of the description of applicability domain, limitations, exclusions 
See 11.1 above. 
It should be noted that the possible additional limitations in the applicability domain identified within 
the validation study are based on the testing of a limited number of chemicals. The selection by the 
VMG of the false negative and false positive threshold values used to decide if a limitation should be 
defined for a given organic functional group is rather subjective and the final conclusions appear to 
rely on single or a very small number of substances without showing a solid rationale for the 
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proposed exclusions. Moreover, the assay is considered as not appropriate for assessing a number of 
metal salts, what raises concerns about other metal salts not appearing in the list.  
The WG recommends providing a sound scientific reason for the exclusion of (groups of) chemicals 
and the presentation of possible assay limitations so that final users can decide whether the assay is 
appropriate for testing their substances before wasting the kits. 
 
 
12. Performance standards (Module 7) 
12.1 Adequacy of the proposed Essential Test Method Components 
The WG cannot offer a reasoned opinion on this. 
In no small part this is due to the fact that the assay matrix has never been chemically characterised, 
and there is no batch-to-batch chemical analysis to ensure consistency; in addition there is a lack of 
transparency about the algorithms applied by the software. 
The ESAC WG therefore cannot determine what might constitute essential test method requirements 
for any assay of this class. 
 
12.2 Adequacy of the Reference Chemicals 
No list of reference chemicals is supplied in the draft PS. The chemicals used for this validation study 
would be suitable only for similar test methods with the same precise applicability domain. 
 
12.3 Adequacy of proposed performance target values 
No performance target values are proposed in the draft PS. These will depend on the selected 
reference chemicals. 
 
 
13. Readiness for standardised use 
13.1 Assessment of the readiness for regulatory purposes 
The performance of the test method for identifying non-classified chemicals (e.g., as first step in a 
Bottom-Up approach) appears to be adequate. However, there are a number of uncertainties related 
with the method that may call into question its acceptance, not least a lack of control over the 
precise chemical composition and structure of the test matrix. However, after consultation with the 
manufacturer, they informed the WG that to date all test kits had been produced from of a single 
batch of plant-extract, and that they still have sufficient in reserve to produce test kits for several 
more years, although it is not clear to the ESAC WG how stable the plant-extract raw material can be 
for 25+ years. 
 
13.2 Assessment of the readiness for other uses  
The method is already in wide use for non-regulatory testing. 
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13.3 Critical aspects impacting on standardised use 
The main factors are the undefined chemical matrix composition (to date only produced from one 
batch of the plant-extract), the unknown variability of the method if performed with matrices 
produced from different bulks of the plant-extract raw material (to date only matrices produced from 
a single bulk have been evaluated), and a lack of transparency about the details of the software. 
 
13.4 Gap analysis 
 Test methods of this class could form components of future integrated testing strategies for 
determining the eye damage/irritation potential of chemicals (Scott et al, 2010). The other 
components of such a testing strategy and the precise role of these test methods have yet to 
be formally defined.  
 The ESAC WG notes that there is limited information on the performance of this test method 
with chemical mixtures and no information about gases and aerosols. 
 The ESAC WG acknowledges that including a wide range of chemical mixtures in validation 
studies currently raises several problems, e.g. availability of in vivo data, selection of test 
mixtures, and continuity of supply. However, most of the substances which have to be 
classified are mixtures and there is a need to confirm that in vitro methods can be used for 
the classification of chemical mixtures. The ESAC WG recommends the inclusion of a broader 
range of chemical mixtures in future validation studies, and proposes consideration of the 
use of reference data available for the classification of mixtures, using the additivity 
approach recommended by the UN GHS (UN, 2015) as well as the CLP (EC, 2008a), and/or the 
use of mixtures already assessed and identified as Cat.1, Cat.2, or No Cat. 
 The chemical matrix is not chemically defined and the stability of the plant-extract raw 
material over time is also not known as far as the ESAC WG is aware, even though the same 
bulk is being used for over 25 years. The batch release Quality Assurance undertaken by the 
manufacturer addresses only test performance not composition. However, taking into 
account the use of a single batch of plant-extract for manufacturing the kits the WG cannot 
give any appraisal on its possible effect on study results. 
 The ESAC WG understands that to date all test kits have been produced from a single batch 
of the plant-based raw material; and that this raw material and the final test kit matrix have 
not been chemically characterised or defined. The ESAC WG also understands that the 
precise chemical composition of the raw material is likely to vary bath-to-batch. This raises 
questions about the composition of the test kit matrix, and the performance of the test 
method, once the current batch of the raw material is exhausted. 
 Much like other validated in vitro methods for identification of Category 1, the OI does not 
address persistence of chemically-induced ocular injuries and consequently is not able to 
correctly predict chemicals classified in vivo as Category 1 due only to persistence of effects. 
Therefore, the use of the OI test method as a first step in a Top-Down approach could result 
in the underprediction of this type of chemicals. 
 If this test method is to be used to identify non-irritants within an Integrated Approach to 
Testing and Assessment (IATA) then the ESAC believes other test methods may be needed to 
assess the vascular and inflammatory components of the adverse outcome pathway for eye 
irritation, and to take account of the lack of epithelial barrier function. 
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14. Other considerations 
The ESAC WG notes that due to the variability of individual animal responses within the in vivo Draize 
eye test there is ≥ 12 % probability, if chemicals are retested, of chemicals currently classified as UN 
GHS Category 2 by the in vivo test being identified as UN GHS No Category (Adriaens et al, 2014). As 
in vivo Draize eye test data served as reference data for chemical selection and Predictive Capacity 
within validation studies, the reported performance of the in vivo test should be borne in mind when 
evaluating the reported performance, and validity, of alternative methods and testing strategies for 
detecting chemically-induced eye damage/irritation. 
 
 
15. Conclusions on the study 
15.1 ESAC WG summary of the results and conclusions of the study 
1. The ESAC WG considers that the performance of the test method appears to be appropriate 
to identify chemicals not requiring classification for serious eye damage/eye irritation under 
UN GHS (UN, 2015). However, there are a number of uncertainties related to the method 
that may call its regulatory acceptance into question. 
2. For use in a Top-Down approach, other than having a long shelf-life and short testing time, 
does not seem to be an advance on other validated test methods for this purpose. Moreover, 
the test method is not intended to provide insights into persistence of chemically-induced 
ocular injuries, which could result in the underprediction of chemicals classified in vivo as Cat 
1 due only to persistence of effects, if the OI test method is used in a Top-Down approach. 
3. Beyond the applicability domain identified before the validation study, from the wide range 
of chemical types, chemical classes, molecular weights, LogP, chemical structures, etc., 
tested in the validation study, no clear, unambiguous additional limitations regarding 
applicability apart from those mentioned above were identified.  
4. The ESAC WG has noted that currently there is only a limited range of chemical mixtures 
available for use as test chemicals within eye damage/irritation validation studies, and would 
like to see more data presented with respect to the test method performance in the case of 
chemical mixtures requiring the classification for eye damage/irritation potential.  
 
15.2 Extent to which study conclusions are justified by the study results alone 
In reaching its conclusions the ESAC WG has also taken account of the larger body of information and 
knowledge set out in the technical annexes supplied, the references cited in the study documents, 
and the answers given directly by the manufacturer to questions formulated directly (orally and in 
written form)  by the WG. It is on consideration of both the study findings, and that larger body of 
knowledge of information, that the ESAC WG established and confirmed the plausibility of the 
conclusions set out above.  
 
15.3 Extent to which conclusions are plausible in the context of existing information 
See 15.2 above. 
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16. Recommendations 
16.1 General recommendations 
On the basis of the above, the ESAC WG does not recommend the use of the OI assay for regulatory 
testing purposes. Nevertheless, considering that (i) the assay is relatively easy and fast to perform, (ii) 
its performance appears to be acceptable, (iii) it is easily shipped and stored, and (iv) it has a long 
shelf-life, the ESAC WG considers that the assay may be useful for screening purposes within the 
applicability domain established in the SOP. Users of the OI assay should nevertheless take into 
consideration that the applicability domain of the method has been poorly defined, being purely 
empirical and not biologically justified. 
 
16.2 Specific recommendations (e.g. concerning improvement of SOPs) 
The OI test method is currently not intended to provide insights into persistence of chemically-
induced ocular injuries. Since this is a current limitation of nearly all validated in vitro methods for 
identification of Category 1, it would be very useful if an OI protocol could be developed to 
differentiate between persistent and reversible ocular effects. 
In addition, if this test method is to be used to identify non-irritants within an Integrated Approach to 
Testing and Assessment (IATA) then the ESAC WG believes other test methods may be needed to 
assess the vascular and inflammatory components of the adverse outcome pathway for eye irritation, 
and to take account of the lack of epithelial barrier function. 
The ESAC WG recommends insights into test performance with chemical mixtures be obtained by 
testing mixtures based on their current classification, or based on the known properties of their 
components. 
The ESAC WG believes that potential problems with the reliability of historical Draize eye test data 
must also be taken into account when evaluating the predictive capacity of alternative test methods 
and testing strategies. 
The ESAC WG recommends replacing "…and 125 μl/mg sample applied…" by "…and 125 μl (liquids) or 
mg (solids) sample, applied…" in the two instances this sentence occurs in figure 3.1 of the SOP to 
improve clarity. Similarly, "μl/mg" in the test method quick work flowchart (page 21 of the SOP) 
should be replaced by "μl (liquids) or mg (solids)". In the way the volumes or weights of test items 
that should be applied to the matrix are currently reported in the SOP (as "µl/mg"), the "/" by 
convention puts the two units in relation to each other and thus could be potentially misunderstood 
as " µl per mg". 
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